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HETEROCYCLIC PEPTIDE KETOAMIDES 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority to U.S. Provisional Appli-
cation No. 61/026,583, filed Feb. 6, 2008, herein incorporated 
by reference in its entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
This invention was made with govermnent support under 
Grant No. 1 R21NS053801 awarded by Public Health Ser-
vices, National Institutes ofHealth. The U.S. Govermnenthas 
certain rights in this invention. 
REFERENCE TO SEQUENCE LISTING 
The Sequence Listing submitted Jun. 11, 2013, as a text file 
named "10034_009US1_2013_06_1 l_Sequence_Lis-
ting.txt," created on Jun. 11, 2013, and having a size of 1 KB 
is hereby incorporated by reference pursuant to 37 C.F.R. 
§ 1.52( e )(5). 
FIELD 
The disclosed subject matter generally relates to peptide 
ketoamide cysteine protease inhibitors. Other aspects of the 
disclosed subject matter relate to methods of using the dis-
closed compositions for inhibiting cysteine proteases such as 
calpain, as well as other cysteine proteases, and for the treat-
ment of various diseases. 
BACKGROUND 
Cysteine proteases such as calpain use a cysteine residue in 
their catalytic mechanism in contrast to serine proteases 
which utilize a serine residue. Cysteine proteases include 
papain, cathepsin B, calpains, and several viral and parasite 
enzymes. Neural tissues, including brain, are known to pos-
sess a large variety of proteases, including at least two cal-
cium stimulated proteases termed calpains. Calpains are 
ubiquitous cytosolic proteolytic enzymes involved in both 
physiological and pathological cellular functions. Limited 
activation of calpains results in modification or activation of 
protein receptors, enzymes, and cytoskeletal proteins. Patho-
logical cellular insults lead to more generalized calpain acti-
vation, resulting in cytoskeletal degradation and cell death. 
Calpain activation likely occurs due to sustained elevation of 
intracellular calcium that is a common feature of models of 
neuronal injury (Bartus, "The cal pain hypothesis of neurode-
generation: evidence for a common cytotoxic pathway," Neu-
roscientist 3:314-27, 1997, which is incorporated by refer-
ence herein in its entirety). 
While calpains degrade a wide variety of protein sub-
strates, cytoskeletal proteins seem to be particularly suscep-
tible to attack. In some cases, the products of the proteolytic 
digestion of these proteins by calpain are distinctive and 
persistent over time. Since cytoskeletal proteins are major 
components of certain types of cells, this provides a simple 
method of detecting calpain activity in cells and tissues. Thus, 
2 
rated by reference herein m its entirety). Activation of 
calpains and/or accumulation of breakdown products of 
cytoskeletal elements have been observed in neural tissues of 
mammals exposed to a wide variety of neurodegenerative 
diseases and conditions. For example, these phenomena have 
been observed following ischemia in gerbils and rats, follow-
ing stroke in humans, following administration of the toxins 
kainate, trimethyltin or colchicine in rats, and in human 
Alzheimer's disease. In the nervous system, calpain activa-
10 tion is believed to be responsible for the calcium-mediated 
cell injury seen in ischemic stroke, spinal cord injury, closed 
head injury, Wallerian degeneration, ALS, and peripheral 
neuropathy. 
Calpains are present, in many tissues in addition to the 
15 brain. Calpain I is activated by micromolar concentrations of 
calcium while calpain II is activated by millimolar concen-
trations. In the brain, calpain II is the predominant form, but 
cal pain I is found at synaptic endings and is thought to be the 
form involved in long term potentiation, synaptic plasticity, 
20 and cell death. Other Ca2+ activated cysteine proteases may 
exist, and the term "calpain" is used to refer to all Ca2+ 
activated cysteine proteases, including calpain I and calpain 
II. The terms "calpain I" and "calpain II" are used herein to 
refer to the micromolar and millimolar activated calpains, 
25 respectively, as described above. 
Cathepsin B, cathepsin L, cathepsin S, and other cathepsins 
are involved in muscular dystrophy, myocardial tissue dam-
age, tumor metastasis, and bone resorption. In addition, a 
number of viral processing enzymes, which are essential for 
30 viral infection, are cysteine proteases. Inhibitors of cysteine 
proteases would thus have multiple therapeutic uses. 
Numerous inhibitors of cal pain and other cysteine protease 
have been described in the literature. These include peptide 
aldehydes such as Ac-Leu-Leu-Nle-H and leupeptin (Ac-
35 Leu-Leu-Arg-H), as well as epoxysuccinates such as E-64. 
These compounds are not especially useful at inhibiting 
cal pain in neural tissue in vivo because they are poorly mem-
brane permeant and, accordingly, are not likely to cross the 
blood brain barrier very well. Also, many of these inhibitors 
40 have poor specificity and will inhibit a wide variety of pro-
teases in addition to calpain. In addition, other classes of 
compounds that inhibit cysteine proteases include peptide 
diazomethyl ketones (Rich, In Protease Inhibitors, Barrett 
and Salvesen, Eds., Elsevier, N.Y., 1986, pp 153-78, which is 
45 incorporated by reference herein). 
Potent calpain inhibitors are in general either transition-
state analogs or irreversible covalent inhibitors. The active 
site of a cysteine protease contains Cys and His residue along 
with the so-called oxyanionhole. The mechanism of substrate 
50 hydrolysis involves the attack of the active site Cys on the 
scissile peptide bond. The active site cysteine of the enzyme 
adds to the scissile amide carbonyl group to form a tetrahedral 
adduct forming an oxyanion that interacts with the so called 
oxyanion hole. Subsequently, the tetrahedral adduct forms an 
55 acyl enzyme intermediate, which is then cleaved to the two 
hydrolysis products. Transition-state analog inhibitors such 
as peptide aldehydes, ketones, and a-ketoamides reversibly 
inhibit cysteine proteases by forming a hemithioacetal 
through reaction with the active site cysteine thiol group. This 
60 resembles the tetrahedral transition state involved in normal 
cal pain activation can be measured indirectly by assaying the 
proteolysis of the cytoskeletal protein spectrin, which pro-
duces a large, distinctive and biologically persistent break- 65 
down product when attacked by calpain (Siman et al., Proc. 
Natl. Acad. Sci. USA 81:3572-76, 1984, which is incorpo-
peptide substrate hydrolysis. Transition state inhibitors are 
very potent reversible inhibitors for cysteine proteases, since 
the enzyme has evolved to bind the tetrahedral transition state 
effectively. 
Additional references to cal pain inhibitors in the literatures 
are Tsujinaka et al., "Synthesis of a new cell-penetrating 
cal pain inhibitor ( calpeptin)," Biochem. Biophys. Res. Com-
US 8,518,885 B2 
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mun. 153: 1201-08, 1988; Huang et al., "Amide derivatives of 
E64c as inhibitors of platelet calpains," J. Med. Chem. 
35:2048-54, 1992; Powers et al., "Irreversible inhibitors of 
serine, cysteine, and threonine proteases," Chem. Rev. 102: 
4639-750, 2002; Powers, "Calpain Inhibitors," In Design of 
Enzyme Inhibitors as Drugs," Sandler and Smith, Eds., 
Oxford University Press, Oxford, 1994; Vol. 2, pp 754-66; 
Donkor, "A survey of calpain inhibitors," Curr. Med. Chem. 
4 
inhibitors, such as peptide a-ketoamides, and methods of 
their use in inhibiting cysteine protease activity, for inhibiting 
calpain activity, and for the treatment of a pathology, for 
example neurodegenerative disease, axonal degeneration, or 
calcium-induced cell injury, or parasitic diseases. 
Additional advantages will be set forth in part in the 
description that follows, and in part will be obvious from the 
description, or may be learned by practice of the aspects 
described below. The advantages described below will be 7: 1171-88, 2000; Krauser and Powers, "Calpain," In Protein-
ase and Peptidase Inhibition: Recent Potential Targets for 
Drug Development, Smith and Simons, Eds., Taylor & Fran-
cis, New York, 2000, pp. 127-53, each of which are incorpo-
rated by reference herein in their entireties. 
10 realized and attained by means of the elements and combina-
tions particularly pointed out in the appended claims. It is to 
be understood that both the foregoing general description and 
the following detailed description are exemplary and 
explanatory only and are not restrictive. Dipeptidyl and tripeptidyl a-ketoesters, a-ketoamides and 
a-ketoacid transition-state inhibitors of calpains I and II have 15 
been reported in the literature. See for example Li et al., 
"Novel peptidyl a-ketoamide inhibitors of calpains and other 
cysteine proteases," J. Med. Chem. 39:4089-98, 1996; Li et 
al., "Peptide a-ketoester, a-ketoamide and a-ketoacid inhibi-
tors of calpains and other cysteine proteases," J. Med. Chem. 20 
36:3472-80, 1993, each of which are incorporated herein by 
reference in their entities. The composition in these publica-
tions are also disclosed in several patents: U.S. Pat. No. 5,514, 
694, issued May 7, 1996, to Powers et al.; U.S. Pat. No. 
5,610,297, issued Mar. 11, 1997, to Powers; U.S. Pat. No. 25 
5,650,508, issued Jul. 22, 1997, to Powers; U.S. Pat. No. 
5,763,576, issued Jun. 9, 1998, to Powers; and U.S. Pat. No. 
6,235,929, issued May 22, 2001, to Powers, each of which are 
incorporated herein by reference in their entireties. 
One of the ketoamides, AK295, is a potent transition-state 30 
inhibitor for calpain I and II, but does have some inhibitory 
activity toward other cysteine proteases such as cathepsins 
BRIEF DESCRIPTION OF THE FIGURE 
The accompanying FIGURE, which is incorporated in and 
constitute a part of this specification, illustrates several 
aspects described below. 
FIG. 1 is a pair of graphs showing the inhibitory effect of 
Z-Leu-Abu-CONH-(CH2kadenin-9-yl, and Z-Leu-Abu-
CONH-(CH2k( 4-methylpiperazin-1-yl) on m-calpain 
(FIG. lA) and µI-II (FIG. lB). Duplicate assays were per-
formed by adding 1.3 µM (EDANS)-EPLFAERK(SEQ ID 
NO:l)-(DABCYL) (A), 125 nM calpain (B), and 4 mM 
CaC12 (C), then averaged to yield the plots shown. Autolytic 
inactivation of m-calpain, but not µI-II, was observed when 
no inhibitor was added (X). Immediately following addition 
of each inhibitor (D), the increase in fluorescence intensity 
was attenuated. Z-Leu-Abu-CONH-(CH2kadenin-9-yl 
(Y), caused a more distinct attenuation of fluorescence in both 
the m-calpain and µI-II assays, indicating that it is a more 
potent inhibitor when compared to Z-Leu-Abu-CONH-
(CH2k( 4-methylpiperazin-1-yl) (Z). 
DETAILED DESCRIPTION 
The materials, compounds, compositions, and methods 
(Li et al., J. Med. Chem. 36:3472-80, 1993). The ketone 
carbonyl group of AK295 is the group which forms the 
hemithioacetal with the active site cysteine of calpain. Since 35 
the enzyme has evolved to bind the tetrahedral transition state 
effectively, transition state inhibitors are usually potent 
reversible inhibitors for cysteine proteases. Reversibility 
occurs when the hemiacetal breaks down to reform the car-
bonyl compound and free enzyme. 
No effective therapy has yet been developed for most neu-
rodegenerative diseases and conditions, and other disease 
related to uncontrolled cysteine protease action. Millions of 
individuals suffer from neurodegenerative diseases, and thus 
there is a need for therapies effective in treating and prevent- 45 
ing these diseases and conditions. There is a need for new 
compositions to treat other diseases related to cysteine pro-
tease activity. Further, because neuronal pathologies have a 
dramatic impact on quality of life of patients, there is a need 
for compositions and methods for treating these disorders, in 50 
particular, compositions and methods for treating pathologies 
with little or reduced side effects such as neuropathy. Thus, 
there is also a need for compositions and methods of treating 
other pathologies related to calpain activation. There is still 
another need for methods and compositions for disease 55 
resulting from other cysteine proteases particularly parasitic 
diseases. The compositions and methods disclosed herein 
address these and other needs. 
40 described herein may be understood more readily by refer-
ence to the following detailed description of specific aspects 
of the disclosed subject matter, the Figures, and the Examples 
included therein. 
SUMMARY 
In accordance with the purposes of the disclosed materials, 
compounds, compositions, and methods, as embodied and 
broadly described herein, the disclosed subject matter, in one 
aspect, relates to compositions and methods for preparing and 
using such compositions. In a further aspect, the disclosed 
subject matter relates to compositions containing calpain 
Before the present materials, compounds, compositions, 
and methods are disclosed and described, it is to be under-
stood that the aspects described below are not limited to 
specific synthetic methods or specific reagents, as such may, 
of course, vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular aspects 
only and is not intended to be limiting. 
Further, disclosed herein are materials, compounds, com-
positions, and components that can be used for, can be used in 
conjunction with, can be used in preparation for, or are prod-
ucts of the disclosed methods and compositions. These and 
other materials are disclosed herein, and it is understood that 
when combinations, subsets, interactions, groups, etc. of 
these materials are disclosed that while specific reference of 
each various individual and collective combinations and per-
mutation of these compounds may not be explicitly disclosed, 
60 each is specifically contemplated and described herein. For 
example, if a compound is disclosed and a number of modi-
fications that can be made to a number of components or 
residues of the compound are discussed, each and every com-
bination and permutation that are possible are specifically 
65 contemplated unless specifically indicated to the contrary. 
Thus, if a class of components A, B, and C are disclosed as 
well as a class of components D, E, and F and an example of 
US 8,518,885 B2 
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a combination composition A-D is disclosed, then even if 
each is not individually recited, each is individually and col-
lectively contemplated. Thus, in this example, each of the 
combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F 
are specifically contemplated and should be considered dis-
closed from disclosure of A, B, and C; D, E, and F; and the 
example combination A-D. Likewise, any subset or combi-
nation of these is also specifically contemplated and dis-
closed. Thus, for example, the sub-group of A-E, B-F, and 
C-E are specifically contemplated and should be considered 
disclosed from disclosure of A, B, andC; D, E, andF; and the 
example combinationA-D. This concept applies to all aspects 
ofthis disclosure including, but not limited to, steps in meth-
ods of making and using the disclosed compositions. Thus, if 
there are a variety of additional steps that can be performed it 
is understood that each of these additional steps can be per-
formed with any specific aspect or combination of aspects of 
the disclosed methods, and that each such combination is 
specifically contemplated and should be considered dis-
closed. 
6 
between values are also disclosed, as appropriately under-
stood by the skilled artisan. For example, ifthe value "10" is 
disclosed, then "less than or equal to 10" as well as "greater 
than or equal to 1 O" is also disclosed. It is also understood that 
throughout the application data are provided in a number of 
different formats and that these data represent endpoints and 
starting points and ranges for any combination of the data 
points. For example, if a particular data point "10" and a 
particular data point "15" are disclosed, it is understood that 
10 greater than, greater than or equal to, less than, less than or 
equal to, and equal to 10 and 15 are considered disclosed as 
well as between 10 and 15. It is also understood that each unit 
between two particular units are also disclosed. For example, 
if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also 
15 disclosed. 
References in the specification and concluding claims to 
parts by weight of a particular component in a composition 
denotes the weight relationship between the component and 
any other components in the composition for which a part by 
20 weight is expressed. Thus, in a compound containing 2 parts 
by weight of component X and 5 parts by weight component 
Y, X andY are present at a weight ratio of2:5, andare present 
in such ratio regardless of whether additional components are 
Also, throughout this specification, various publications 
are referenced. The disclosures of these publications in their 
entireties are hereby incorporated by reference into this appli-
cation in order to more fully describe the state of the art to 
which the disclosed matter pertains. The references disclosed 25 
are also individually and specifically incorporated by refer-
ence herein for the material contained in them that is dis-
cussed in the sentence in which the reference is relied upon. 
contained in the compound. 
A weight percent (wt. % ) of a component, unless specifi-
cally stated to the contrary, is based on the total weight of the 
formulation or composition in which the component is 
included. 
DEFINITIONS 
In this specification and in the claims that follow, reference 
will be made to a number of terms, which shall be defined to 
have the following meanings: 
Throughout the specification and claims the word "com-
prise" and other forms of the word, such as "comprising" and 
"comprises," means including but not limited to, and is not 
intended to exclude, for example, other additives, compo-
nents, integers, or steps. 
As used in the description and the appended claims, the 
singular forms "a," "an," and "the" include plural referents 
unless the context clearly dictates otherwise. Thus, for 
example, reference to "a compound" includes mixtures of 
two or more such compounds, reference to "an agent" 
includes mixtures of two or more such agents, reference to 
"the composition" includes mixtures of two or more such 
compositions, and the like. 
"Optional" or "optionally" means that the subsequently 
described event or circumstance can or cannot occur, and that 
the description includes instances where the event or circum-
stance occurs and instances where it does not. 
Ranges can be expressed herein as from "about" one par-
ticular value, and/or to "about" another particular value. 
When such a range is expressed, another aspect includes from 
the one particular value and/or to the other particular value. 
Similarly, when values are expressed as approximations, by 
use of the antecedent "about," it will be understood that the 
particular value forms another aspect. It will be further under-
stood that the endpoints of each of the ranges are significant 
both in relation to the other endpoint, and independently of 
the other endpoint. It is also understood that there are a 
number of values disclosed herein, and that each value is also 
herein disclosed as "about" that particular value in addition to 
the value itself. For example, ifthe value "10" is disclosed, 
then "about 1 O" is also disclosed. It is also understood that 
when a value is disclosed that "less than or equal to" the value, 
"greater than or equal to the value," and possible ranges 
"Subject," as used herein, means an individual. In one 
30 aspect, the subject is a mammal such as a primate, and, in 
another aspect, the subject is a human. The term "subject" 
also includes domesticated animals (e.g., cats, dogs, etc.), 
livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and 
laboratory animals (e.g., mouse, rabbit, rat, guinea pig, fruit 
35 fly, etc.). 
By the term "effective amount" of a compound or compo-
sition as provided herein is meant a nontoxic but sufficient 
amount of the compound to provide the desired utility, for 
example to reduce, inhibit, prevent, or heal neuronal injury. 
40 As will be pointed out below, the exact amount required will 
vary from subject to subject, depending on the species, age, 
body weight, general health, sex, diet, and general condition 
of the subject, the severity of the condition or disease that is 
being treated, the particular compound used, its mode of 
45 administration, the duration of the treatment; drugs used in 
combination or coincidental with the specific composition 
employed, and like factors well known in the medical arts. 
Thus, it is not possible to specify an exact "effective amount"; 
however, an appropriate effective amount can be determined 
50 by one of ordinary skill in the art using only routine experi-
mentation. For example, it is well within the skill of the art to 
start doses of a composition at levels lower than those 
required to achieve the desired therapeutic effect and to 
gradually increase the dosage until the desired effect is 
55 achieved. One can also evaluate the particular aspects of the 
medical history, signs, symptoms, and objective laboratory 
tests that are known to be useful in evaluating the status of a 
subject in need of attention for the treatment of a disease. 
These signs, symptoms, and objective laboratory tests will 
60 vary, depending upon the particular disease or condition 
being treated or prevented, as will be known to any clinician 
who treats such patients or a researcher conducting experi-
mentation in this field. For example, if, based on a comparison 
with an appropriate control group and/or knowledge of the 
65 normal progression of the disease in the general population or 
the particular individual: 1) a subject's physical condition is 
shown to be improved, 2) the progression of the disease or 
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condition is shown to be stabilized, or slowed, or reversed, or 
3) the need for other medications for treating the disease or 
condition is lessened or obviated, then a particular treatment 
regimen will be considered efficacious. If desired, the effec-
tive daily dose can be divided into multiple doses for purposes 
of administration. Consequently, single dose compositions 
can contain such amounts or submultiples thereof to make up 
the daily dose. The dosage can be adjusted by the individual 
physician or the subject in the event of any counterindica-
tions. Dosage can vary, and can be administered in one or 
more dose administrations daily, for one or several days. 
Guidance can be found in the literature for appropriate dos-
ages for given classes of pharmaceutical products. 
8 
derived from the structure of the compounds disclosed herein 
and whose structure is sufficiently similar to those disclosed 
herein and based upon that similarity, would be expected, by 
one skilled in the art, to exhibit the same or similar activities 
and utilities as the claimed compounds. 
As used herein, the term "substituted" is contemplated to 
include all permissible substituents of organic compounds. In 
a broad aspect, the permissible substituents include acyclic 
and cyclic, branched and unbranched, carbocyclic and het-
10 erocyclic, and aromatic and nonaromatic substituents of 
organic compounds. Illustrative substituents include, for 
example, those described below. The permissible substituents 
can be one or more (e.g., referred to as "disubstitued," "trisub-
stituted," and the like) and the same or different for appropri-The terms "higher," "increases," "elevates," or "enhanced" 
refer to increases above basal levels, e.g., as compared to a 
control. The terms "lower," "decreases," "reduces," or 
"reduction" refer to decreases below basal levels, e.g., as 
compared to a control. By "control" is meant either a subject, 
organ, tissue, or cell lacking a disease or injury, or a subject, 
organ, tissue, or cell in the absence of a particular variable 20 
such as a therapeutic agent. A subject, organ, tissue, or cell in 
the absence of a therapeutic agent can be the same subject, 
organ, tissue, or cell before or after treatment with a thera-
peutic agent or can be a different subject, organ, tissue, or cell 
15 ate organic compounds. For purposes of this disclosure, the 
heteroatoms, such as nitrogen and oxygen, can have hydrogen 
substituents and/or any permissible substituents of organic 
compounds described herein which satisfy the valences of the 
heteroatoms. This disclosure is not intended to be limited in 
any manner by the permissible substituents of organic com-
pounds. Also, the terms "substitution" or "substituted with" 
include the implicit proviso that such substitution is in accor-
dance with permitted valence of the substituted atom and the 
substituent, and that the substitution results in a stable com-
in the absence of the therapeutic agent. Comparison to a 25 
control can include a comparison to a known control level or 
value known in the art. Thus, basal levels are normal in vivo 
levels prior to, or in the absence of, the addition of an agent 
(e.g., a therapeutic agent) or another molecule. The term 
"modulate" is used herein to refer to an increase or decrease, 30 
as defined herein. 
pound, e.g., a compound that does not spontaneously undergo 
transformation such as by rearrangement, cyclization, elimi-
nation, etc. Also, as used herein "substitution" or "substituted 
with" is meant to encompass configurations where one sub-
stituent is fused to another substituent. For example, an aryl 
group substituted with an aryl group (or vice versa) can mean 
that one aryl group is bonded to the second aryl group via a 
The term "pharmaceutically acceptable" means a material 
that is not biologically or otherwise undesirable, i.e., the 
material can be administered to an individual along with the 
selected bicyclic compound without causing any undesirable 35 
biological effects or interacting in a deleterious manner with 
any of the other components of the pharmaceutical composi-
tion in which it is contained. 
single sigma bond and also that the two aryl groups are fused, 
e.g., two carbons of one alkyl group are shared with two 
carbons of the other aryl group. 
The term "alkyl" as used herein is a branched or 
unbranched saturated hydrocarbon group of 1 to 20 carbon 
atoms (C1 _20), such as methyl (C1), ethyl (C2 ), n-propyl (C3 ), 
isopropyl (C3 ), n-butyl (C4 ), isobutyl (C5 ), t-butyl (C5 ), pen-
tyl (C5 ), hexyl (C6 ), heptyl (C7 ), octyl (C8), nonyl (C9 ), decyl The term "pharmaceutically acceptable salt(s)," unless 
otherwise indicated, includes salts of acidic or basic groups 
that may be present in the compounds of Formula I. 
The compounds of Formula I that are basic in nature are 
capable of forming a wide variety of salts with various inor-
ganic and organic acids. The acids that may be used to prepare 
pharmaceutically acceptable acid addition salts of such basic 
compounds of Formula I are those that form non-toxic acid 
addition salts, i.e., salts containing pharmacologically accept-
able anions, such as the hydrochloride, hydrobromide, 
hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phos-
phate, isonicotinate, acetate, lactate, salicylate, citrate, acid 
citrate, tartrate, TFA, pantothenate, bitartrate, ascorbate, suc-
cinate, maleate, gentisinate, fumarate, gluconate, glucaro-
nate, saccharate, formate, benzoate, glutamate, methane-
sulfonate, ethanesulfonate, benzenesulfonate, 
p-toluenesulfonate and pamoate (i.e., 1, 1 '-methylene-bis-(2-
hydroxy-3-naphthoate )) salts. Those compounds of the For-
mula I that are acidic in nature are capable of forming base 
salts with various pharmacologically acceptable cations. 
Examples of such salts include the alkali metal or alkaline 
earth metal salts and particularly, the sodium and potassium 
salts. 
The term "pharmaceutically acceptable derivative" refers 
to any homolog, analog, or fragment corresponding to the 
peptide ketoamides disclosed herein, which inhibits protease 
activity and is relatively non-toxic to the subject or host. 
As used herein, and without limitation, the term "deriva-
tive" is used to refer to any compound which has a structure 
40 (C10), dodecyl (C12), tetradecyl (C14), hexadecyl (C16), octa-
decyl (C18), eicosyl (C20), and the like. The alkyl group can 
also be substituted or unsubstituted. The alkyl group can be 
substituted with one or more groups including, but not limited 
to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl, 
45 heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, 
halide, hydroxy, ketone, sulfo-oxo, sulfonylamino, nitro, 
silyl, azide, nitro, nitrile, or thiol, as described below. A 
"lower alkyl" is a branched orunbranched alkyl group with up 
to six carbon atoms (C1 _6), e.g., methyl, ethyl, propyl, isopro-
50 pyl, butyl, isobutyl, t-butyl, pentyl, and hexyl. The term "C1_ 
10 alkyl" as used herein refers to a branched or unbranched 
alkyl with up to 10 carbon atoms, such as methyl, ethyl, 
n-propyl, isopropyl, n-butyl, isobutyl, I-butyl, and the like or 
branched or unbranched hydrocarbon groups of carbon atoms 
55 that either contain double or triple carbon bonds. Other terms 
for a group of alkyl substituents, such as C1 _4 alkyl and C1 _8 
alkyl, which are branched or unbranched hydrocarbon groups 
with 4 or 8 carbon atoms, respectively, are also used herein. 
Throughout the specification "alkyl" is generally used to 
60 refer to both unsubstituted alkyl groups and substituted alkyl 
groups; however, substituted alkyl groups are also specifi-
cally referred to herein by identifying the specific 
substituent(s) on the alkyl group. For example, the term 
"alkyl halide" specifically refers to an alkyl group that is 
65 substituted with one or more halides, e.g., fluorine, chlorine, 
bromine, or iodine. Similarly, the term "aralkyl" refers to an 
alkyl group substituted with an aryl group. When "alkyl" is 
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used in one sentence and a specific term such as "alky 1 halide" 
or "aralkyl" is used in another, it is not meant to imply that the 
term "alkyl" does not also refer to specific terms such as 
"alkyl halide" or "aralkyl" and the like. 
This practice is also used for other groups described herein. 
10 
aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, 
ether, halide, hydroxy, ketone, sulfo-oxo, sulfonylamino, 
azide, nitro, nitrile, or thiol as described herein. The term 
"biaryl" is a specific type of aryl group and is included in the 
definition of aryl. Biaryl refers to two aryl groups that are 
bound together via a fused ring structure, as in naphthalene, or 
are attached via one or more carbon-carbon bonds, as in 
biphenyl. 
That is, while a term such as "heteroaryl" refers to both 
unsubstituted and substituted heteroaryl moieties, the substi-
tuted moieties can, in addition, be specifically identified 
herein; for example, a particular substituted heteroaryl can be 
referred to as, e.g., an "alkyl heteroaryl." Similarly, a substi-
tuted alkenyl can be, e.g., an "alkenyl halide," and the like. 
Again, the practice of using a general term, such as "het-
eroaryl," and a specific term, such as "alkyl heteroaryl," is not 
meant to imply that the general term does not also include the 
specific term. 
The term "cycloalkyl" as used herein is a non-aromatic 
10 
carbon-based ring composed of at least three carbon atoms. 
Examples of cycloalkyl groups include, but are not limited to, 
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, 
etc. The term "heterocycloalkyl" is a cycloalkyl group as 
15 defined above where at least one of the carbon atoms of the 
The term "alkoxy" as used herein is an alkyl or cycloalkyl 
group bonded through an ether linkage; that is, an "alkoxy" 
group can be defined as -OR where R is alkyl or cycloalkyl 
as defined herein. A "lower alkoxy" is a C1 _6 alkoxy group 
with up to six carbon atoms, e.g., methoxy, ethoxy, propoxy, 20 
butoxy, pentoxy, and hexoxy. The term "C1 _10 alkoxy," as 
used herein, refers to a C1 _10 alkyl group as defined herein 
attached to the parent molecular group through an oxygen 
atom. The term C1_4 alkoxy refers to C1 _4 alkyl groups as 
definedherein attached to the parent molecular group through 25 
an oxygen atom, and so forth. 
The term "alkenyl" as used herein is a hydrocarbon group 
of from 2 to 20 carbon atoms with a structural formula con-
taining at least one carbon-carbon double bond. Asymmetric 
structures such as (R 1R2 )C=C(R3R4 ) are intended to include 30 
both the E and Z isomers. This can be presumed in structural 
formulae herein wherein an asymmetric alkene is present, or 
it can be explicitly indicated by the bond symbol C=C. The 
alkenyl group can be substituted with one or more groups 
including, but not limited to, alkyl, halogenated alkyl, alkoxy, 35 
alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxy-
ring is substituted with a heteroatom such as, but not limited 
to, nitrogen, oxygen, sulfur, or phosphorus. The cycloalkyl 
group and heterocycloalkyl group can be substituted or 
unsubstituted. The cycloalkyl group and heterocycloalkyl 
group can be substituted with one or more groups including, 
but not limited to, alkyl, alkoxy, alkenyl, alkynyl, aryl, het-
eroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, 
hydroxy, ketone, sulfo-oxo, sulfonylamino, nitro, azide, 
nitrile, silyl, or thiol. The term "C3 _15 cycloalkyl" as applied 
herein is meant to include cyclic hydrocarbon chains. 
Examples of these cyclic hydrocarbon chains include cyclo-
propane, cyclobutane, cyclopentane, cyclohexane, cyclohep-
tane, cyclooctane, cyclononane, cyclodecane, cyclounde-
cane, etc. 
The term "cycloalkenyl" as used herein is a non-aromatic 
carbon-based ring composed of at least three carbon atoms 
and contains at least one double bound, e.g., C=C. Examples 
of cycloalkenyl groups include, but are not limited to, cyclo-
propenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, 
cyclohexenyl, cyclohexadienyl, and the like. The term "het-
erocycloalkenyl" is a type of cycloalkenyl group as defined 
above, and is included within the meaning of the term 
"cycloalkenyl," where at least one of the carbon atoms of the 
lic acid, ester, ether, halide, hydroxy, ketone, sulfo-oxo, sul-
fonylamino, nitro, silyl, azide, nitro, nitrile, or thiol. As with 
alkyl, the terms "lower alkenyl," "C1 _10 alkenyl," "C1-4 alk-
enyl," and the like are similarly defined. 
The term "alkynyl" as used herein is a hydrocarbon group 
of 2 to 20 carbon atoms with a structural formula containing 
at least one carbon-carbon triple bond. The alkynyl group can 
40 ring is substituted with a heteroatom such as, but not limited 
to, nitrogen, oxygen, sulfur, or phosphorus. The cycloalkenyl 
group and heterocycloalkenyl group can be substituted or 
unsubstituted. The cycloalkenyl group and heterocycloalk-
enyl group can be substituted with one or more groups includ-
ing, but not limited to, alkyl, alkoxy, alkenyl, alkynyl, aryl, 
heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, 
halide, hydroxy, ketone, sulfo-oxo, sulfonylamino, nitro, 
silyl, azide, nitrile, or thiol. 
The term "cyclic group" is used herein to refer to either aryl 
be substituted with one or more groups including, but not 
limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, 45 
aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, 
ether, halide, hydroxy, ketone, sulfo-oxo, sulfonylamino, 
nitro, silyl, azide, nitro, nitrile, or thiol. As with alkyl, the 
terms "lower alkynyl," "C1 _10 alkynyl," "C1-4 alkynyl," and 
the like are similarly defined. 50 groups (e.g., heteraryl, biaryl), non-aryl groups (i.e., 
cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocy-
cloalkenyl groups), or both. Cyclic groups have one or more 
ring systems that can be substituted or unsubstituted. A cyclic 
The term "aliphatic" as used herein refers to a non-aro-
matic hydrocarbon group and includes branched and 
unbranched alkyl, alkenyl, or alkynyl groups. 
The term "aryl" as used herein is a group that contains any 
carbon-based aromatic group including, but not limited to, 55 
benzene, benzyl, naphthalene, phenyl, biphenyl, phenoxy-
benzene, and the like. The term "aryl" also includes "het-
eroaryl," which is defined as a group that contains an aromatic 
group that has at least one heteroatom incorporated within the 
ring of the aromatic group. Examples ofheteroatoms include, 60 
but are not limited to, nitrogen, oxygen, sulfur, and phospho-
rus. Likewise, the term "non-heteroaryl," which is also 
included in the term "aryl," defines a group that contains an 
aromatic group that does not contain a heteroatom. The aryl 
group can be substituted or unsubstituted. The aryl group can 65 
be substituted with one or more groups including, but not 
limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, 
group can contain one or more aryl groups, one or more 
non-aryl groups, or one or more aryl groups and one or more 
non-aryl groups. 
The terms "amine" or "amino," as used herein, refers to 
-NH2 or derivatives thereof formed by independent replace-
ment of one or both hydrogen atoms thereon with a substitu-
ent or substituents independently selected from alkyl, 
alkanoyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, het-
eroaryl, heteroarylalkyl, and an amino protecting group. The 
term "C1_10 alkylamino," as used herein, refers to a C1_10 alkyl 
group, as defined herein, to which is attached at least one 
amino substituent. The term "C2 _12 dialkylamino," as used 
herein, refers to two C 1 _10 alky 1 groups, as defined herein, that 
are attached to an amino substituent. 
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The term "C1_10 fluoroalkyl," as used herein, refers to a 
C1_10 alkyl group, as defined herein, to which is attached at 
least one fluorine substituent. 
The term "C1_10 perfluoroalkyl," as used herein, refers to a 
cl-10 alkyl group in which all of the hydrogen atoms have 
been replaced with fluorine atoms. 
The term "carboxylic acid" as used herein is represented by 
the formula-C(O)OH. Theterm "carboxylate" is a carboxy-
12 
lines contemplates each possible isomer, e.g., each enanti-
omer and diastereomer, and a mixture of isomers, such as a 
racemic or scalemic mixtures. 
Reference will now be made in detail to specific aspects of 
the disclosed materials, compounds, compositions, compo-
nents, devices, articles, and methods, examples of which are 
illustrated in the following description and examples, and in 
the figures and their previous and following description. 
Materials and Compositions 
Disclosed herein are compositions that comprise a class of 
peptidyl a-ketoamides that can be used for selectively inhib-
iting cysteine proteases such as calpain and generally inhib-
iting all cysteine proteases. Cysteine proteases are involved in 
numerous disease states and inhibitors for these enzymes can 
lic acid that has been deprotonated, i.e., --C(O)O-. Proto-
nation and deprotonation can be achieved by changes in pH. 10 
The terms "carboxylic acid" and "carboxylate" are under-
stood to be interchangeable. Also, throughout the specifica-
tion the abbreviation C(O) is understood to represent a car-
bonyl group C=O. 15 be used therapeutically forthe treatment of diseases involving 
cysteine proteases. It has been discovered and is disclosed 
herein that peptidyl a-ketoamides can be constructed to 
inhibit selectively cysteine proteases or groups of cysteine 
proteases. Ketoamides with aromatic amino acid residues in 
The term "ester" as used herein is represented by the for-
mula -OC(O)R or--C(O)OR, where R can be a substituted 
or unsubstituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, 
alkynyl, cycloalkynyl, aryl, or heteroaryl group as described 
herein. 
The term "ether" as used herein is represented by the for-
mula ROR, where each R can be, independently of the other, 
a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, 
cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group 
described herein. 
The term "halide" as used herein refers to the halogens 
fluorine, chlorine, bromine, and iodine. 
The term "hydroxyl" as used herein is represented by the 
formula -OH. 
The term "ketone" as used herein is represented by the 
formula RC(O)R, where each R can be, independently of the 
other, a substituted or unsubstituted alkyl, cycloalkyl, alk-
enyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl 
group as described herein. 
20 the Pl site would be good inhibitors for cysteine proteases 
such as papain, cathepsin B, and calpain I and II. Thus, they 
would have utility as anticancer agents. Ketoamides with 
either aromatic amino acid residues or small hydrophobic 
alkyl amino acid residues at Pl are good inhibitors of cal pain 
25 I and II. Ketoamides with small alkyl amino acid residues 
such as Leu or Val at P2 are also good inhibitors of the 
calpains. Ketoamides which contain a heterocyclic base or 
choline-like moieties also are not only potent inhibitors for 
calpain, but have the ability to be transported into cells par-
30 ticularly in the nervous system. The ketoamides which are 
calpain inhibitors would be useful as neuroprotectants and 
can be used as therapeutics for the treatment of neurodegen-
eration, stroke, restenosis, ALS, muscular dystrophy, and 
related diseases. 
The term "nitro" as used herein is represented by the for- 35 
mula-N02. 
In discussing the interactions of peptides with cysteine 
proteases, the nomenclature of Schechter and Berger (Bio-
chem. Biophys. Res. Commun. 27: 157-62, 1967) is utilized 
throughout this specification. The individual amino acid resi-
dues of a substrate or an inhibitor are designated Pl, P2, etc. 
The term "nitrile" as used herein is represented by the 
formula --CN. 
The term "thiol" as used herein is represented by the for-
mula -SH. 
The term "isocyanate" as used herein is represented by the 
formula -NCO. 
The term "sulfo-oxo" as used herein is represented by the 
formulas-S(O)R, -S(0)2R, -OS(0)2R, or-OS(0)20R, 
where R can be hydrogen or a substituted or unsubstituted 
alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalky-
40 and the corresponding subsites of the enzyme are designated 
Sl, S2, etc. The scissile bond of the substrate is Sl-Sl '.The 
primary substrate recognition site of serine proteases is S 1. 
The most important recognition sub sites of cysteine proteases 
such as calpain are Sl and S2. With cysteine proteases, there 
45 are additional recognition sites at the prime subsites such as 
Sl' and S2'. 
ny 1, ary 1, or heteroary 1 group as described herein. Throughout 
this specification "S(O)" is a short hand notation for S=O. 
The term "sulfonyl" is used herein to refer to the sulfo-oxo 
group represented by the formula -S(0)2R, where R can be 50 
hydrogen or a substituted or unsubstituted alkyl, cycloalkyl, 
alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or het-
eroary 1 group as described herein. The term "sulfone" as used 
herein is represented by the formula RS(0)2R, where each R 
can be, independently, a substituted or unsubstituted alkyl, 55 
cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, 
aryl, or heteroaryl group as described herein. The term "sul-
foxide" as used herein is represented by the formula RS(O)R, 
where each R can be, independently, a substituted or unsub-
stituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, 60 
cycloalkynyl, aryl, or heteroaryl group as described herein. 
Amino acid residues and blocking groups are designated 
using standard abbreviations (see J. Biol. Chem. 260:14-42, 
1985, for nomenclature rules, which is incorporated by ref-
erence herein). An amino acid residue (AA) in a peptide or 
inhibitor structure refers to the part structure -NH-
CHR 1-CO-, where R1 is the side chain of the amino acid 
residue AA. An amino acid a-ketoester residue would be 
designated -AA-CO-OR, which represents the part struc-
ture -NH-CHR1--CO-CO---OR. Thus, the ethyl 
ketoester derived from benzoyl alanine would be designated 
Bz-Ala-CO-OEt which represents C6H5CO-NH-
CHMe-CO-CO---OEt. Likewise, peptide ketoamide resi-
dues would be designated -AA-CO-NH-R respectively. 
Thus, the ethylketo amide derived from Z-Leu-Phe-OH 
would be designated Z-Leu-Phe-CO-NH-Et which repre-
sents C6H5CH20CO-NH--CH(CH2CHMe2)-CO-
NH--CH(CH2Ph)-CO--CO-NH-Et. 
The abbreviation Mu refers to morpholinocarbonyl, 
O(CH2CH2)2N--CO-. The abbreviation PhPr refers to phe-
nylpropanoyl, and Hph to homophenylalanine. The abbrevia-
tion Pip-CO-refers to an N-piperidylcarbonyl group. 
Unless stated to the contrary, a formula with chemical 
bonds shown only as solid lines and not as wedges or dashed 
The peptide alpha-ketoamides of this composition are 
65 abbreviated as M-AA2-AA1-CO-NH-(CH2)n-R3 . The 
ketoamide portion of the molecule, -AA1-CO-NH 
-(CH2)n-R3 , is equivalent to -NHCHR1CO-CO-
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NH-(CH2)6-R3 where the R 1 is the side chain of AA 1 . Thus 
the peptide alpha-ketoamideAK295 is abbreviated as Z-Leu-
Abu-CONH-(CH2k4-morpholinyl (AK295). The Z is a 
benzyloxycarbonyl group, Leu is a leucine residue, Abu is an 
alpha-aminobutanoic acid residue, the ketone carbonyl group 5 
is part of the Abu residue, CONH is the amide of the a-ke-
toamide, and the 4-morpholinyl group is a morpholine bound 
to the methylene chair through the nitrogen atom of the mor-
pholine ring. The structure of the peptide a-ketoamide 
AK295, abbreviated as Z-Leu-Abu-CONH-(CH2k4-mor- 10 




Disclosed herein is a class of dipeptide a-ketoamides that 
has the formula M-AA2-AA1-CO-NH-(CH2)n-R3 (re- 25 
ferred to herein as "Formula I"). This formula is based on the 
nomenclature of Schechter and Berger discussed above. For-
mula I can also be represented by the following structural 
formula, where R 2 and R 1 represent the side chains of amino 
acidresiduesAA2 andAA1 respectively. 30 
Disclosed herein are compositions of Formula I, M-AA2- 40 
AA 1-CO-NH-(CH2)n -R3 , or a pharmaceutically accept-
able salt, wherein 
M is selected from the group consisting ofY -FG, 
14 
1-naphthyl, 1-naphthyl monosubstituted with J, 2-naph-
thyl, 2-naphthyl monosubstituted with J, 2-pyridyl, 3-py-
ridyl, and 4-pyridyl; 
J is selected from the group consisting of halogen, OH, CN, 
N02, NH2, COOH, C02Me, C02Et, CF3 , C1 _6 alkyl, C1 _4 
alkoxy, and, cl-4 perfluoroalkyl; 
AA2 is an amino acid with the L configuration, D configura-
tion, or DL configuration at the a-carbon and is selected 
from the group consisting of alanine, valine, leucine, iso-
leucine, praline, histidine, methionine, methionine sulfox-
ide, phenylalanine, serine, threonine, phenylglycine, nor-
leucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, S-ethyl-
cysteine, S-benzylcysteine, NH2-CH(CH2CHEt2)-




anoic acid, thiaproline, and hexafluoroleucine; 
AA 1 is an amino acid with the L configuration, D configura-
tion, or DL configuration at the a-carbon and is selected 
from the group consisting of alanine, valine, leucine, iso-
leucine, praline, histidine, methionine, methionine sulfox-
ide, phenylalanine, arginine, lysine, tryptophan, glycine, 
serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, phenylglycine, 
norleucine, norvaline, alpha-aminobutyric acid, 0-meth-
ylserine, 0-ethylserine, S-methylcysteine, S-ethylcys-
teine, S-benzylcysteine, NH2---CH(CH2CHEt2)-COOH, 
alpha-aminoheptanoic acid, NH2-CH(CH2-l-naphthyl)-
COOH, NH2-CH(CH2-2-naphthyl)-COOH, NH2---CH 
(CH2-cyclohexyl)-COOH, NH2-CH(CH2-cyclopentyl)-
COOH, NH2---CH(CH2-cyclobutyl)-COOH, NH2---CH 
(CH2-cyclopropyl)-COOH, 5,5,5-trifluoroleucine, 
homophenylalanine, hexafluoroleucine, a-aminohexanoic 
acid, phenylalanine monosubstituted on the phenyl group 
with K, and homophenylalanine monosubstituted on the 
phenyl group with K; 
K is selected from the group consisting of halogen, C1 _6 alkyl, 
and cl-4 alkoxy; 
n is an integer from 1 to 5; 
45 
R3 is selected from the group consisting of /\ 
O\__JN-CO-, 
/\ 
Me-N N-CO-\___j , 
CN-CO-, and 
FG is selected from the group cons1stmg of -CO-, 
---0---CO-, -NH---CO-, -S02-, -NH-S02-, 
-NH---CS-, H---CO-, NH2-CO-NH2-S02-, 
50 
55 
and NH2-CS; 60 
y is selected from the group consisting of cl-8 alkyl, c3-15 
cycloalkyl, cl-4 alkyl monosubstituted with phenyl, cl-4 
alkyl disubstituted with phenyl, C1_4 alkyl mono substituted 
with Ar, C1 _4 alkyl monosubstituted with 1-naphthyl, C1 _4 
alkyl monosubstituted with 2-naphthyl, andAr; 65 
Ar is selected from the group consisting of phenyl, phenyl 
monosubstituted with J, phenyl disubstituted with J, 
N5=NH2 N 
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-N-Me· \ , 
Me 
4· ' ' n ' 
R is selected from th . . 55 and benzyl; e group cons1stmg ofC1-6 alkyl, phenyl, 
Rs is selected from the grou consi f 
and benzyl; and p s mg ofC1-6 alkyl, phenyl, 
R 6 is selected fi h . . and benzyl. rom t e group cons1stmg ofC1-6 alkyl, phenyl, 
60 
Exemplary Structures 
In one example of the disclosed d" . 
the compound is benzyl (2S -1- 1- i:eptJd~ a-ketoam_ides, 
65 yl)propylamino)-1 2 d" ) ( (3 (6-ammo-9H-punn-9-
' - wxopentan-3-ylamino) 4 h 1 
oxopentan-2-ylcarbamate Thi . - -met y -1-ture A. . s compound is shown in Struc-
US 8,518,885 B2 
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This structure corresponds to Formula I when M is Y-FG, 
FG is 0---CO-, Y is benzyl, AA2 is leucine, AA1 is a-ami- 15 
nobutanoic acid (Abu), n is 3, and R3 is: 
20 
25 
Further examples of peptide a-ketoamides disclosed 
herein include, but are not limited to, the compounds in Table 
1. 30 
TABLE 1 
Z-Leu-Abu-CONH-(CH2 ) 3-adenin-9-yl, 
Z-Leu-Phe-CONH-(CH2 ) 3-adenin-9-yl, 
Z-Leu-Hph-CONH-(CH2 ) 3-adenin-9-yl, 
Z-Val-Abu-CONH-(CH2 ) 3-adenin-9-yl, 
Z-Val-Phe-CONH-(CH2 h-adenin-9-yl, 
Z-Val-Hph-CONH-(CH2 ) 3-adenin-9-yl, 
Z-Leu-Abu-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Z-Leu-Phe-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Z-Leu-Hph-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Z-Val-Abu-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Z-Val-Phe-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Z-Val-Hph-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Z-Leu-Abu-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Z-Leu-Phe-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Z-Leu-Hph-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Z-Val-Abu-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Z-Val-Phe-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Z-Val-Hph-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Z-Leu-Abu-CONH-(CH2 ) 3-cytosin-3-yl, 
Z-Leu-Phe-CONH-(CH2 ) 3-cytosin-3-yl, 
Z-Leu-Hph-CONH-(CH2 ) 3-cytosin-3-yl, 






Z-Val-Abu-CONH-(CH2 h-( 4-methylpiperazin-1-yl), 
Z-Val-Phe-CONH-(CH2 h-(4-methylpiperazin-1-yl), 
Z-Val-Hph-CONH-(CH2h-(4-methylpiperazin-1-yl), 
Z-Leu-Abu-CONH-(CH2 ) 3-N(CH3 )o, 
Z-Leu-Phe-CONH-(CH2 ) 3-N(CH3)o, 
Z-Leu-Hph-CONH-(CH2 ) 3-N(CH3)o, 
Z-Val-Abu-CONH-(CH2 ) 3-N(CH3)o, 


















Mu-Leu-Abu-CONH-(CH2 ) 3-adenin-9-yl, 
Mu-Leu-Phe-CONH-(CH2 ) 3-adenin-9-yl, 
Mu-Leu-Hph-CONH-(CH2 ) 3-adenin-9-yl, 
Mu-Val-Abu-CONH-(CH2 ) 3-adenin-9-yl, 
Mu-Val-Phe-CONH-(CH2 ) 3-adenin-9-yl, 
Mu-Val-Hph-CONH-(CH2 ) 3-adenin-9-yl, 
Mu-Leu-Abu-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Mu-Leu-Phe-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Mu-Leu-Hph-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Mu-Val-Abu-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Mu-Val-Phe-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Mu-Val-Hph-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Mu-Leu-Abu-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Mu-Leu-Phe-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Mu-Leu-Hph-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Mu-Val-Abu-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Mu-Val-Phe-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Mu-Val-Hph-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Mu-Leu-Abu-CONH-(CH2 ) 3-cytosin-3-yl, 
Mu-Leu-Phe-CONH-(CH2 ) 3-cytosin-3-yl, 
Mu-Leu-Hph-CONH-(CH2 ) 3-cytosin-3-yl, 
Mu-Val-Abu-CONH-(CH2 ) 3-cytosin-3-yl, 
Mu-Val-Phe-CONH-(CH2 ) 3-cytosin-3-yl, 







Mu-Leu-Abu-CONH-(CH2 ) 3-N(CH3)o, 
Mu-Leu-Phe-CONH-(CH2 ) 3-N(CH3)o, 
Mu-Leu-Hph-CONH-(CH2 ) 3-N(CH3 )o, 
Mu-Val-Abu-CONH-(CH2 ) 3-N(CH3 )o, 
Mu-Val-Phe-CONH-(CH2 ) 3-N(CH3)o, 







Pip-CO-Leu-Abu-CONH-(CH2 ) 3-adenin-9-yl, 
Pip-CO-Leu-Phe-CONH-(CH2 ) 3-adenin-9-yl, 
Pip-CO-Leu-Hph-CONH-(CH2 ) 3-adenin-9-yl, 
Pip-CO-Val-Abu-CONH-(CH2 ) 3-adenin-9-yl, 
Pip-CO-Val-Phe-CONH-(CH2 ) 3-adenin-9-yl, 
Pip-CO-Val-Hph-CONH-(CH2 ) 3-adenin-9-yl, 
Pip-CO-Leu-Abu-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Pip-CO-Leu-Phe-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Pip-CO-Leu-Hph-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Pip-CO-Val-Abu-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Pip-CO-Val-Phe-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Pip-CO-Val-Hph-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
Pip-CO-Leu-Abu-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Pip-CO-Leu-Phe-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Pip-CO-Leu-Hph-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Pip-CO-Val-Abu-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Pip-CO-Val-Phe-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Pip-CO-Val-Hph-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
Pip-CO-Leu-Abu-CONH-(CH2 ) 3-cytosin-3-yl, 
Pip-CO-Leu-Phe-CONH-(CH2 ) 3-cytosin-3-yl, 
Pip-CO-Leu-Hph-CONH-(CH2 ) 3-cytosin-3-yl, 
US 8,518,885 B2 
19 
TABLE I-continued 
Pip-CO-Val-Abu-CONH-(CH2 ) 3 -cytosin-3-yl, 
Pip-CO-Val-Phe-CONH-(CH2 ) 3-cytosin-3-yl, 
Pip-CO-Val-Hph-CONH-(CH2 ) 3-cytosin-3-yl, 
Pip-CO-Leu-Abu-CONH-(CH2h-( 4-methylpiperazin-1-yl ), 
Pip-CO-Leu-Phe-CONH-(CH2h-(4-methylpiperazin-1-yl), 




Pip-CO-Leu-Abu-CONH-(CH2 ) 3-N(CH3)o, 
Pip-CO-Leu-Phe-CONH-(CH2 ) 3-N(CH3)o, 
Pip-CO-Leu-Hph-CONH-(CH2 ) 3-N(CH3 )2 , 
Pip-CO-Val-Abu-CONH-(CH2 ) 3-N(CH3 )2 , 




Pip-CO-Leu-Hph-CONH-(CH2 )2-N(CH3 )2 , 
Pip-CO-Val-Abu-CONH-(CH2 )2-N(CH3 )2 , 
Pip-CO-Val-Phe-CONH-(CH2 )o-N(CH3 )2 , 
Pip-CO-Val-Hph-CONH-(CH2)o-N(CH3)o, 
PhPr-Leu-Abu-CONH-(CH2 ) 3-adenin-9-yl, 
PhPr-Leu-Phe-CONH-(CH2 ) 3-adenin-9-yl, 
PhPr-Leu-Hph-CONH-(CH2 ) 3-adenin-9-yl, 
PhPr-Val-Abu-CONH-(CH2 ) 3-adenin-9-yl, 
PhPr-Val-Phe-CONH-(CH2 ) 3-adenin-9-yl, 
PhPr-Val-Hph-CONH-(CH2 ) 3-adenin-9-yl, 
PhPr-Leu-Abu-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
PhPr-Leu-Phe-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
PhPr-Leu-Hph-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
PhPr-Val-Abu-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
PhPr-Val-Phe-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
PhPr-Val-Hph-CONH-(CH2 ) 3-2-methyladenin-9-yl, 
PhPr-Leu-Abu-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
PhPr-Leu-Phe-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
PhPr-Leu-Hph-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
PhPr-Val-Abu-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
PhPr-Val-Phe-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
PhPr-Val-Hph-CONH-(CH2 ) 3-2-methoxyadenin-9-yl, 
PhPr-Leu-Abu-CONH-(CH2 ) 3-cytosin-3-yl, 
PhPr-Leu-Phe-CONH-(CH2 ) 3-cytosin-3-yl, 
PhPr-Leu-Hph-CONH-(CH2 ) 3-cytosin-3-yl, 
PhPr-Val-Abu-CONH-(CH2 ) 3-cytosin-3-yl, 
PhPr-Val-Phe-CONH-(CH2 ) 3-cytosin-3-yl, 
PhPr-Val-Hph-CONH-(CH2 ) 3-cytosin-3-yl, 
PhPr-Leu-Abu-CONH-(CH2h-(4-methylpiperazin-1-yl), 
PhPr-Leu-Phe-CONH-(CH2h-( 4-methylpiperazin-1-yl), 




PhPr-Leu-Abu-CONH-(CH2 ) 3-N(CH3)o, 
PhPr-Leu-Phe-CONH-(CH2 ) 3-N(CH3)o, 
PhPr-Leu-Hph-CONH-(CH2 ) 3-N(CH3 )2 , 
PhPr-Val-Abu-CONH-(CH2 ) 3-N(CH3 )2 , 
PhPr-Val-Phe-CONH-(CH2 ) 3-N(CH3 )2 , 
PhPr-Val-Hph-CONH-(CH2 ) 3-N(CH 3)o, 
PhPr-Leu-Abu-CONH-(CH2)o-N(CH3)o, 
PhPr-Leu-Phe-CONH-(CH2)o-N(CH3)o, 
PhPr-Leu-Hph-CONH-(CH2 )o-N(CH3 )2 , 
PhPr-Val-Abu-CONH-(CH2 )o-N(CH3 )2 , 
PhPr-Val-Phe-CONH-(CH2)o-N(CH3 )2' and 
PhPr-Val-Hph-CONH-(CH2)o-N(CH 3)o. 
The compounds disclosed here are unlike those of Donkor 
et al. ("Synthesis, calpain inhibitory activity, and cytotoxicity 
of P2-substituted pro line and thiaproline peptidyl aldehydes 
and peptidyl alpha-ketoamides," J. Med. Chem. 49:5282-90, 
2006), which discloses a-ketoamides with P2 praline and 
substituted praline residues. Donkor et al.'s ketoamides do 
not have a heterocyclic ring system or an amine or a quater-
nary amino R3 . They also have no nitrogens in the R3 group. 
Similarly, Lescop et al. ("Novel cell-penetrating alpha-
keto-amide cal pain inhibitors as potential treatment for mus-
cular dystrophy," Bioorg. Med. Chem. Lett. 15: 17 6-81, 2005) 
discloses a-ketoamides that possess a lipoyl moiety at the P3 
position. These ketoamides do not have a heterocyclic ring 
20 
system or an amine or a quaternary amino R3 . They also have 
no nitrogens in the R3 group and disulfide linkage in M. 
Donkor et al. ("Synthesis and cal pain inhibitory activity of 
alpha-ketoamides with 2,3-methanoleucine stereoisomers at 
the P2 position," Bioorg. Med. Chem. Lett. 10:2497-500, 
2000) discloses a-ketoamides with 2,3-methanoleucine ste-
reoisomers at the P2 position. These ketoamides do not have 
a heterocyclic ring system or an amine or a quaternary amino 
R3 group. These structures also have no nitrogens in the R3 
10 group. Further, Donkor et al.'s ketoamides have cyclopro-
pane rings in AA 2 . 
Moreover, Weyermann et al. ("Synthesis and evaluation of 
calpain inhibitors carrying muscle cell targeting groups," 
Lett. Drug Design & Discovery 3: 152-8, 2006) discloses 
15 a-ketoamides carrying different muscle cell targeting groups 
at the amino terminus. These ketoamides do not have a het-
erocyclic ring system or an amine or a quaternary amino R3 . 
These structures also have no nitrogens in the R3 group. 
Weyermann et al.' s compounds also have amino acid residues 
20 at M. 
Shirasaki et al. ("Exploration of orally available calpain 
inhibitors. Part 3: Dipeptidyl alpha-ketoamide derivatives 
containing pyridine moiety," Bioorg. Med. Chem. 14: 5691-8, 
2006) discloses a-ketoamides containing a pyridine moiety at 
25 P3. These ketoamides do not have a heterocyclic ring system 
or an amine or a quaternary amino R3 . These structures also 
have no nitrogens in the R3 group. Shirasaki et al.'s com-
pounds also have a cyclopropane ring and no spacer in place 
of -(CH2 )n -R3 . 
30 Shirasaki et al. ("Exploration of orally available calpain 
inhibitors: peptidyl alpha-ketoamides contammg an 
amphiphile at P3 site," Bioorg. Med. Chem. 13:4473-84, 
2005) discloses a-ketoamides with an amphiphile at the P3 
position. These ketoamides do not have a heterocyclic ring 
35 system or an amine or a quaternary amino as R3 . These 
structures also have no nitrogens in the R3 group. 
Lee et al. ("Synthesis and biological evaluation of 
chromone carboxamides as calpain inhibitors," Bioorg. Med. 
Chem. Lett. 15:2857-60, 2005) discloses a-ketoamides con-
40 taining chromone derivatives in the P2-P3 region. These 
ketoamides do not have a heterocyclic ring system or an 
amine or a quaternary amino R3 . Lee et al.'s structures also 
have no nitrogens in the R3 group. These compounds are not 
dipeptides and do not have anAA2 in their structures. 
45 Bihovsky et al. ("1,2-Benzothiazine 1,1-dioxide alpha-ke-
toamide analogues as potent calpain I inhibitors" Bioorg. 
Med. Chem. Lett. 14:1035-8, 2004) discloses 1,2-benzothi-
azine 1, I-dioxide a-ketoamides as calpain I inhibitors. These 
ketoamides do not have a heterocyclic ring system or an 
50 amine or a quaternary amino R3 . These structures also have 
no nitrogens in theR3 group. Bihovsky et al.'s compounds are 
not dipeptides and do not have AA2 in their structures. 
Donkor et al. (Design, synthesis, molecular modeling stud-
ies, and cal pain inhibitory activity of novel alpha-ketoamides 
55 incorporating polar residues at the Pl '-position," J. Med. 
Chem. 4 7 :72-9, 2004) discloses a-ketoamides containing ste-
reoisoremic residues with different electronic properties at 
the Pl' position. These ketoamides do not have a heterocyclic 
ring system or an amine or a quaternary amino R3 . These 
60 structures also have no nitrogens in the R3 group. Also, 
Donkor et al.'s compounds have functional groups or het-
eroatoms on -(CH2 )n -R3 . 
Lubisch et al. ("Benzoylalanine-derivedketoamides carry-
ing vinylbenzyl amino residues: discovery of potent water-
65 soluble calpain inhibitors with oral bioavailability," J. Med. 
Chem. 46:2404-12, 2003) discloses a-ketoamides containing 
vinylbenzyl amino residues in the P2-P3 position. These 
US 8,518,885 B2 
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ketoamides do not have a heterocyclic ring system or an 
amine or a quaternary amino R3 . These structures also have 
no nitrogens in the R3 group. Lubisch et al.'s compounds are 
not dipeptides and do not have AA 2 in their structures. 
Lubisch et al. ("Discovery of phenyl alanine derivedketoa- 5 
mides carrying benzoyl residues as novel calpain inhibitors," 
Bioorg. Med. Chem. Lett. 12: 1335-8, 2002) discloses a-ke-
toamides carrying a benzoyl residue. These ketoamides do 
not have a heterocyclic ring system or an amine or a quater-
nary amino R3 . These structures also have no nitrogens in the 10 
R3 group. Lubisch et al.'s compounds are not dipeptides and 
do not have AA 2 in their structures. 
Chatterjee et al. (P2-achiral, P'-extended alpha-ketoamide 
inhibitors of calpain I," Bioorg. Med. Chem. Lett. 9:2371-4, 15 
1999) discloses P2 -achiral, P'-spanning a-ketoamide inhibi-
tors. These ketoamides do not have a heterocyclic ring system 
or a amine or a quaternary amino R3 . These structures also 
have no nitrogens in the R3 group. Chatterjee et al.'s com-
pounds are not dipeptides and do not have AA 2 in their struc- 20 
tures. 
Donkor ("A survey of calpain inhibitors," Curr. Med. 
Chem. 7: 1171-88, 2000) reviews calpain inhibitors including 
ketoamides. The ketoamides disclosed in the review do not 
have a heterocyclic ring system or an amine or a quaternary 25 
amino R3 . The structures also have no nitrogens in the R3 
group. 
Further, a series of ketoamides have been synthesized as 
inhibitors for cathepsin K. However, these ketoamides do not 
have a heterocyclic ring system or an amine or a quaternary 30 
amino R3 . Their structures also have no nitrogens in the R3 
group. These compounds are not dipeptides and they do not 
have AA2 in their structures. References are Catalano et al., 
"Design of small molecule ketoamide-based inhibitors of 
cathepsin K," Bioorg. Med. Chem. Lett. 14:719-22, 2004; 35 
Tavares et al., "Ketoamide-based inhibitors of cysteine pro-
tease, cathepsin K: P3 modifications," J. Med. Chem. 
47:5057-68, 2004; Tavares et al., "Potent and selective ketoa-
mide-based inhibitors of cysteine protease, cathepsin K," J. 
Med. Chem. 47:5049-56, 2004; Barrett et al., "Novel, potent 40 
P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin 
K inhibitors," Bioorg. Med. Chem. Lett. 16:1735-9, 2006; 
Barrett et al., "P2-P3 conformationally constrained ketoam-
ide-based inhibitors of cathepsin K," Bioorg. Med. Chem. 
Lett. 15:3540-6, 2005; Barrett et al., "A structural screening 45 
approach to ketoamide-based inhibitors of cathepsin K," 
Bioorg. Med. Chem. Lett. 15:2209-13, 2005; Barrett et al., 
"Potent and selective P2-P3 ketoamide inhibitors of cathepsin 
K with good pharmacokinetic properties via favorable Pl', 
Pl, and/or P3 substitutions," Bioorg. Med. Chem. Lett. 50 
14:4897-902, 2004; and Barrett et al., "Orally bioavailable 
small molecule ketoamide-based inhibitors of cathepsin K," 
Bioorg. Med. Chem. Lett. 14:2543-6, 2004, which are each 
incorporated by reference herein in their entirities. 
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Stuttgart in 1974 (both references are incorporated by refer-
ence herein in their entireties for their teachings of peptide 
syntheses). 
The M-group of Formula I can be introduced using a num-
ber of different reaction schemes. For example it can be 
introduced directly on an amino acid as shown in Scheme 1 
(top), or the M-group can be introduced by reaction with an 
amino acid ester, followed by removal of the ester group by 
hydrolysis to give the same product (Scheme 1, bottom). 
Scheme 1. Synthesis ofM-substituted amino acid precursors, 
M-AA2 -0Hor M-AA2-0R'. 
-
- -




The techniques for introduction of the M-group are well 
documented in The Peptides, Houben-Wey!, and many other 
textbooks on organic synthesis. For example reaction with 
cyanate or p-nitrophenyl cyanate introduces a carbamyl 
group (M=NH2CO-). Reaction with MeNHCOCI intro-
duces the MeNHCO- group. Reaction with p-nitrophenyl 
thiocarbamate introduces a thio carbamyl group 
(M=NH2CS-). Reaction with NH2 S02 Cl introduces the 
NH2 S02 - group. Reaction with MeNHS02 Cl introduces 
the MeNHS02 -group. Reaction with a substituted alkyl or 
aryl isocyanate introduces the Y-NH-CO- group where 
Y is a substituted alkyl or aryl group. Reaction with a substi-
tuted alkyl or aryl isothiocyanate introduces the Y-NH-
CS- group where Y is a substituted alkyl or aryl group. 
Reaction with Y-S02-Cl introduces the Y-S02 - group. 
Reaction with a substituted alkyl or aryl acid chloride intro-
duces an acyl group (M=Y-CO-). For example, reaction 
with Ph-CH2 CH2-CO--Cl gives the Y-CO- group 
where Y is a C3 alkyl substituted with a phenyl group. Reac-
tion with a substituted alkyl or aryl thioacid chloride intro-
duces a thioacyl group (M=Y--CS-). Reaction with a sub-
stituted alkyl or aryl sulfonyl chloride introduce a Y-S02 -
group. For example reaction with naphthyl sulfonyl chloride 
would give the Y-S02- derivative where Y was a naphthyl 
Synthetic Methods 
The synthesis of the compositions disclosed herein com-
prises several steps: 1) synthesis of dipeptide precursors, 2) 
synthesis of dipeptide esters and acids, 3) synthesis of pre-
cursor amines, and 4) synthesis of the new peptide ketoam-
ides. Each of these steps is discussed below. 
55 group. Reaction with a substituted alkyl or aryl chloroformate 
introduces a Y-0---CO- group. Reaction with a substi-
tuted alkyl or aryl chlorothioformate introduces a Y-0-
CS-. There are many alternate reaction schemes that can be 
used to introduce all of the above M-groups to give either 
60 M-AA2 -0H or M-AA2 -0R'. 
1. Synthesis of Peptide Precursors 
The precursor peptide can be prepared using standard pep-
tide chemistry which is well described in publications such as 
The Peptides, Analysis, Synthesis, Biology, Vol. 1-9, pub-
lished in 1979-1987 by Academic Press and Houben-Wey! 65 
Methoden der Organischen Chemie, Vol. 15, Parts 1 and 2, 
Synthese van Peptiden, published by Georg Thieme Verlag, 
The M-AA2 -0H derivatives can then be used directly to 
synthesize ketoamide using various synthetic methods or can 
be converted into the di peptides M-AA 2 -AA 1-0 H, which can 
then be used in the Dakin-West reaction. The substituted 
dipeptides M-AA2 -AA1-0H can also be prepared directly 
from H-AA2 -AA1-0H using the reactions described above 
for introduction of the M-group. Alternately, the M-group can 
US 8,518,885 B2 
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be introduced by reaction with carboxyl blocked peptides to 
give M-AA2 -AA1-0R', followed by the removal of the block-
ing group R'. The techniques for introduction of the M-group 
into amino acids and peptide is well documented in The 
Peptides, Houben-Wey!, and many other textbooks on 
organic synthesis. 
The M-group can also be introduced by first synthesizing a 
Z-blocked dipeptide ketoamide, de blocking the Z group from 
final ketoamide product, and then reaction with an appropri-
ate acylating or sulfonylation agent. An example of this strat- 10 
egy is shown in Scheme 2. 
Scheme 2. Introduction of the M-group directly into dipeptide ketoamides. 
15 
0 R2 0 
~O)l~~~y1y~-(CH2)n-R3 -
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20 (i) 1. NaOH, 2. HCI orH,, Pd/C (ii) HCl•H2N-AA1-0R,HOBt,DCC,DMF 
(iii) 1. NaOH, 2. HCI or H,, Pd/C 
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2. Synthesis of Peptide Ketoesters and Ketoacids 
The a-ketoamide inhibitors can be prepared from the cor-
responding dipeptide a-ketoesters or a-ketoacids. The a-ke-
toester can be prepared by a two step Dakin-West reaction 
from the corresponding dipeptide acid (M-AA2 -AA1-0H) as 
0 R1 0 
30 shown in Scheme 4 (Charles et al., J. Chem. Soc. Perkin l, 
1139-1146, 1980, which is incorporated by reference herein 
in its entirety). When the M-group is a morpholinocarbonyl group (Mu=O 
(CH2CH2 ) 2N--CO-) or a similar structure, the synthesis 
can involve an isocyanate derivative of the amino acid ester. 
Scheme 3 shows this synthetic scheme. An amino acid methyl 35 
ester or benzyl ester isocyanate, which can be synthesized 
from the corresponding amino acid hydrochloride salt 
according to the procedure by Nowick et al., is dissolved in 
CH2 Cl2 and cooled down to 0° C. (J. Org. Chem. 57:7364-6, 
1992, which is incorporated by reference herein in its 40 
entirety). Morpholine is added to the stirred solution of amino 
acid methyl ester or benzyl ester isocyanate. The reaction 
mixture is stirred vigorously for about 16 hours at room 
temperature. The solvent is removed and purification on a 
silica gel colunm chromatography gives the desired product. 45 
The methyl ester or the benzyl ester of the product is hydro-
lyzed and then reacted with the corresponding amino acid 
methyl ester or benzyl ester using standard peptide coupling 
reactions. Deprotection of the methyl or benzyl ester gives the 
corresponding peptide acid. 
Scheme 3. General procedure for the introduction 













Scheme 4. Procedure for the synthesis of di peptide ketoesters and 
ketoacids via a Dakin-West reaction. 
The dipeptide acid 3a is Z-Leu-Abu-OH and 3b is Z-Leu-Phe-OH. 
e.~Oy~yl~~OH 













i) DMAP, Pyridine, EtOCOCOCl/THF. ii) NEt3/EtOH. iii) NaOH/MeOH. 
The R group in the ketoester structures can be introduced 
during the Dakin-West reaction by reaction with an oxalyl 
chloride Cl-CO--C0-0-R. In Scheme 4, it is ethyl. 
10 
There are numerous other methods for the synthesis of 15 
dipeptide ketoesters, ketoacids, and ketoamides. These syn-
thetic methods have been reviewed by Chu and Powers, "Pep-
tide a-Oxo Esters, a-Oxo Acids, and a-Oxoamides," In 
Houben-Wey! Methods of Organic Chemistry. Synthesis of 
Peptides and Peptidomimetics, Goodman et al., Eds., Georg 20 
Thieme Verlag, Stuttgart and New York, Vol. E 22d, 2003, pp. 
244-55, which is incorporated by reference herein. 
3. Synthesis of Precursor Amines 
A first general procedure for the synthesis of the precursor 
amines involves the reaction of secondary amines with diha- 25 
loalkanes to add the linker by a single alkylation reaction. The 
second halogen on the linker can then be reacted with sodium 
azide to obtain the corresponding azide derivatives. The cata-
26 
Then catalytic reduction of the nitriles with palladium acti-
vated on carbon and hydrogen gas gives the desired precursor 
amines (Scheme 6). 
Scheme 6. General procedure for the synthesis of precursor amines 
via reaction with acrylonitrile. 
Some precursor amines are commercially available includ-
ing 2-dimethylaminopropylamine and dimethylaminoethy-
lamine. These compounds are available fromAcros Organics 
and Aldrich. 
4. Synthesis ofKetoamide Products 
Ketoamides M-AA2 -AA1-CONHR can be prepared indi-
rectly from the ketoesters. The ketone carbonyl group can be 
first protected as shown in Scheme 7 and then the ketoamide 
can be prepared by reaction with an amine (RNH2 ). The 
product can be easily isolated from the reaction mixture when 
using this procedure. This procedure will also work with 
other ketone protecting groups. 
Scheme 7. Synthesis ofketoamides from blocked ketoesters . 
....... ~yo YR1 o ,....-Et 




lytic reduction of the azides in the presence of palladium 
activated on carbon and hydrogen gas gives the precursor 
amines (Scheme 5). 
Scheme 5. General procedure for the synthesis of precursor amines 
via a dihaloalkane. 
A second general procedure involves reaction of secondary 
amines with acrylonitrile to attach the linker on the amine. 
50 
Another synthetic procedure involves use of the ketoacid 
obtained by hydrolysis of the corresponding ketoester. The 
ketoacid can be used as a precursor to the a-ketoamide via 
coupling with an amine (RNH2 ) using standard peptide cou-
pling reagents, which results in formation of the peptide 
55 a-ketoamide (Scheme 8). 
60 
Scheme 8. Synthesis ofketoamides from ketoacids. 
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-continued 
0 R1 0 
M/~0~~!YR 
R2 0 
Pharmaceutical Compositions and Methods of Use 
28 
sules, syrups, or elixirs. Dosage levels of the order of0.2 mg 
to 140 mg per kilogram of body weight per day are useful in 
the treatment of the above-indicated conditions (10 mg to 7 
gm per patient per day). The amount of active ingredient that 
may be combined with carrier materials to produce a single 
dosage form will vary depending upon the host treated and the 
particular mode of administration. 
For injection, the therapeutic amount of the peptide ketoa-
mides or their pharmaceutically acceptable salts, derivatives 
10 or prodrugs will normally be in the dosage range from 0.2 to 
140 mg/kg of body weight. Administration is made by intra-
venous, intramuscular, or subcutaneous injection. Accord-
ingly, pharmaceutical compositions for parenteral adminis-
tration will contain from about 10 mg to 7 gm of the 
Also disclosed herein are pharmaceutical compositions 
that comprise a compound according to Formula I and a 
pharmaceutically accepted carrier, diluent, or excipient. 
Accordingly, the compounds of Formula I can be used in the 
manufacture of a medicament. Pharmaceutical compositions 
can also include thickeners, buffers, preservatives, surface 
active agents and the like in addition to the compounds dis-
closed herein. Pharmaceutical compositions can also include 
one or more additional active ingredients such as antimicro-
bial agents, anti-inflammatory agents, anesthetics, and the 
like. In one specific example, the disclosed pharmaceutical 20 
compositions can comprise a compound according to For-
mula I and a pharmaceutically acceptable carrier and an anti-
hyperproliferative agent 
15 compounds per dose. In addition to the active ingredient, 
these pharmaceutical compositions will usually contain a 
buffer, e.g. a phosphate buffer which keeps the pH in therange 
from 3.5 to 7 and sodium chloride, mannitol, or sorbitol for 
adjusting the isotonic pressure. 
A composition for topical application can be formulated as 
an aqueous solution, lotion, jelly or an oily solution or sus-
pension, ointments, creams, gels, drops, suppositories, 
sprays, liquids and powders. Conventional pharmaceutical 
carriers, aqueous, powder or oily bases, thickeners and the Pharmaceutical carriers are known to those skilled in the 
art. These most typically would be standard carriers for 
administration of drugs to humans, including solutions such 
as sterile water, saline, and buffered solutions at physiological 
pH. Suitable carriers and their formulations are described in 
Remington: The Science and Practice of Pharmacy, 21st Ed., 
Lippincott Williams & Wilkins, Philadelphia, Pa., 2005, 
which is incorporated by reference herein for its teachings of 
carriers and pharmaceutical formulations. Typically, an 
appropriate amount of a pharmaceutically-acceptable salt is 
used in the formulation to render the formulation isotonic. 
Examples of the pharmaceutically-acceptable carrier include, 
but are not limited to, saline, Ringer's solution and dextrose 
solution. The pH of the solution can be from about 5 to about 
8 (e.g., from about 7 to about 7.5). Further carriers include 
sustained release preparations such as semipermeable matri-
ces of solid hydrophobic polymers containing the disclosed 
compounds, which matrices are in the form of shaped articles, 
e.g., films, liposomes, microparticles, or microcapsules. It 
will be apparent to those persons skilled in the art that certain 
carriers can be more preferable depending upon, for instance, 
the route of administration and concentration of composition 
being administered. Other compounds can be administered 
according to standard procedures used by those skilled in the 
art. 
The disclosed pharmaceutical formulations can be used 
therapeutically orprophylactically. They can be administered 
in a number of ways depending on whether local or systemic 
treatment is desired, and on the area to be treated. Adminis-
tration can be topically (including ophthalmically, vaginally, 
rectally, intranasally), orally, by inhalation, or parenterally, 
for example by intravenous drip, subcutaneous, intraperito-
neal or intramuscular injection, intrasternal injection, or infu-
sion techniques. The disclosed compounds can be adminis-
tered intravenously, intraperitoneally, intramuscularly, 
subcutaneously, intracavity, or transdermally. The dosage 
depends primarily on the specific formulation and on the 
object of the therapy or prophylaxis. The amount of the indi-
vidual doses as well as the administration is best determined 
by individually assessing each case. 
The pharmaceutical compositions containing the active 
ingredient can be in a form suitable for oral use, for example, 
as tablets, troches, lozenges, aqueous or oily suspensions, 
dispersible powders or granules, emulsions, hard or soft cap-
25 like can be desirable. A composition in the form of an aqueous 
solution is obtained by dissolving the compounds disclosed 
herein in aqueous buffer solution of pH 4 to 6.5 and, if desired, 
adding a polymeric binder. An oily formulation for topical 
application is obtained by suspending the compounds dis-
30 closed herein in an oil, optionally with the addition of a 
swelling agent such as aluminium stearate and/or a surfactant. 
Preparations for parenteral administration include sterile 
aqueous or non-aqueous solutions, suspensions, and emul-
sions. Examples of non-aqueous solvents are propylene gly-
35 col, polyethylene glycol, vegetable oils such as olive oil, 
marine oils, and injectable organic esters such as ethyl oleate. 
Aqueous carriers include water, alcoholic/aqueous solutions, 
and emulsions or suspensions, including saline and buffered 
media. Parenteral vehicles include sodium chloride solution, 
40 Ringer's dextrose, dextrose and sodium chloride, lactated 
Ringer's, and fixed oils. Intravenous vehicles include fluid 
and nutrient replenishers, electrolyte replenishers (such as 
those based on Ringer's dextrose), and the like. Preservatives 
and other additives may also be present such as, for example, 
45 antimicrobials, anti-oxidants, chelating agents, and inert 
gases and the like. 
Some of the formulations can potentially be administered 
as a pharmaceutically acceptable acid- or base-addition salt, 
formed by reaction with inorganic acids such as hydrochloric 
50 acid, hydrobromic acid, perchloric acid, nitric acid, thiocya-
nic acid, sulfuric acid, and phosphoric acid, and organic acids 
such as formic acid, acetic acid, propionic acid, glycolic acid, 
lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic 
acid, maleic acid, and fumaric acid, or by reaction with an 
55 inorganic base such as sodium hydroxide, ammonium 
hydroxide, potassium hydroxide, and organic bases such as 
mono-, di-, trialkyl and aryl amines and substituted ethano-
lamines. 
The disclosed compounds and compositions can be used to 
60 treat a pathology, in particular a neural pathology such as 
nerve degeneration. The nerve degeneration can be related to 
diabetes or neurotoxic agents. One example provides a 
method for treating a neurodegenerative disease by adminis-
tering to a patient a therapeutically effective amount of a 
65 compound of the Formula I. Examples of such neurodegen-
erative disorders are stroke, Alzheimer's disease, Parkinson's 
disease, multiple sclerosis, neuropathies, Huntington's dis-
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ease, dentatorubropallidoluysian atrophy, spinocerebellar 
atrophy type 3, spinal bulbar muscular atrophy, and myo-
trophic lateral sclerosis. 
30 
DMF was evaporated, and the residue was redissolved in 
EtOAc. The organic layer was washed with 2% citric acid, 
saturated NaHC03 , saturated NaCl, dried over MgS04 , and 
concentrated. Purification on a silica gel column with the 
EXAMPLES 
The following examples are set forth below to illustrate the 
methods and results according to the disclosed subject matter. 
These examples are not intended to be inclusive of all aspects 
of the subject matter disclosed herein, but rather to illustrate 
representative methods and results. These examples are not 
intended to exclude equivalents and variations of the present 
invention, which are apparent to one skilled in the art. 
5 proper eluant gave the compound Mu-Ala-Ala-OCH3 . This 
compound was then hydrolyzed in MeOH using NaOH (1 M 
aqueous, 1.1 eq) under standard deb locking conditions to give 
the Mu-Ala-Ala-OH, the dipeptide acid precursor (Mu=O 
(CH2 CH2 ) 2N-CO-). This procedure is illustrated in 10 Scheme 9. 
Efforts have been made to ensure accuracy with respect to 
numbers (e.g., amounts, temperature, pH, etc.) but some 
errors and deviations should be accounted for. Unless indi-
cated otherwise, parts are parts by weight, temperature is in ° 
C. or is at ambient temperature, and pressure is at or near 
atmospheric. There are numerous variations and combina-
tions of conditions, e.g., component concentrations, tempera-
tures, pressures, and other reaction ranges and conditions that 
can be used to optimize the product purity and yield obtained 
from the described process. Only reasonable and routine 




Certain materials, compounds, compositions, and compo-
nents disclosed herein can be obtained commercially or 
readily synthesized using techniques generally known to 
those of skill in the art. For example, the starting materials and 
reagents used in preparing the disclosed compositions are 30 
either available from commercial suppliers such as Aldrich 
Chemical Co., (Milwaukee, Wis.), Acros Organics (Morris 
Plains, N.J.), Fisher Scientific (Pittsburgh, Pa.), or Sigma (St. 
Louis, Mo.) or are prepared by methods known to those 
skilled in the art following procedures set forth in references 35 
such as Fieser and Fieser's Reagents for Organic Synthesis, 
Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chem-
istry of Carbon Compounds, Volumes 1-5 and Supplements 
(Elsevier Science Publishers, 1989); Organic Reactions, Vol-
umes 1-40 (John Wiley and Sons, 1991); March's Advanced 40 
Organic Chemistry, (John Wiley and Sons, 4th Edition); and 
Larock's Comprehensive Organic Transformations (VCH 





Alanine methyl ester isocyanate, which was synthesized 50 
from the corresponding amino acid hydrochloride salt 
according to the procedure by Nowick et al., was dissolved in 
CH2 Cl2 and cooled down to 0° C. Morpholine was added to 
the stirred solution of alanine methyl ester isocyanate. The 
reaction mixture was stirred vigorously for 16 hours at room 55 
temperature. After removal of solvent, the crude product was 
purified by a silica gel column chromatography. The methyl 
ester group ofMu-Ala-OCH3 was hydrolyzed in MeOH using 
NaOH (1 M aqueous, 1.1 eq) under standard deblocking 
conditions. Mu-Ala-OH was then coupled to alanine methyl 60 
ester hydrochloride (HCl.NH2 -Ala-OCH3 ) using the DCC/ 
HOBt coupling method. To a stirred solution of the Mu-Ala-
OH (1 eq) in DMF at -15° C., HOBt (1.5 eq) was added. The 
hydrochloride salt of the alanine methyl ester was pretreated 
with NMM (1.5 eq) at -15° C. DMF prior to addition. DCC 65 
(1.5 eq) was added to the solution and the reaction mixture 
was allowed to react for 16 hours at room temperature. The 
H1N 















0~ 0 R1 
(i) 1. NaOH, 2. HCI or H,, Pd/C (ii) HCl•H2N-Ala-OR, HOB!, DCC, DMF 
(iii) 1. NaOH, 2. HCI or H,, Pd/C 
Example 2 
Synthesis ofN-Cbz-Leu-Abu-COOEt and 
N-Cbz-Leu-Phe-COOEt (Sa and 5b from Scheme 4) 
The general experimental conditions for the Dakin-West 
acylation and the hydrolysis reaction are given in this proce-
dure. These general reactions are also discussed above and are 
shown in Scheme 4. The quantities of the reagents, reaction 
times, and the product yields are listed in Table 2. To 50 mL 
ofTHF, 0.02 mole (1 equivalent) of the dipeptide acid (3a or 
3b in Scheme 4), 4-dimethylaminopyridine (DMAP), pyri-
dine, and ethyl oxalyl chloride were added sequentially. The 
resulting mixture was stirred at reflux temperature for 2 to 6 
hours. After removing the heat source, 1 M HCl (50 mL) was 
added to the brown solution. The mixture was extracted with 
ethyl acetate (2x100 mL). The combined extract was washed 
with 100 mL of saturated NaCl, dried over MgS04 overnight, 
and filtered. Ethyl acetate was removed from the filtrate to 
give a mixture of products containing the dipeptidyl enol ester 
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(4a or4b in Scheme 4), as identified by MS (FAB mode): 4a, 
thin layer chromatography (TLC, solvent A) Rf=0.6S; MS 
(calculated for M+l, C25H35N20 9 , S07) mle S07; 4b, TLC 
(solvent A) Rf=O.S3; MS (calculated for M+l, C30H37N20 9 , 
S69) mle S69. The mixture of products was dissolved in 20 s 
mL of absolute ethanol and stirred in an ice bath. Triethy-
lamine (2.8 mL, 1 equivalent) was added in one portion and 
stirring was continued for 1-4 hours at room temperature. 
Solvent was removed from the final mixture using a rotary 
evaporator. The crude oil was subjected to colunm chroma- 10 
tography to give 8.8-lS.O mmol (44-76%) of the dipeptidyl 
a-keto ester (Sa or Sb in Scheme 4) as a light yellow oil: Sa, 
TLC (solvent A) Rf=0.37; 1 H NMR (CDC13 ) o=0.86-0.93 (m, 
9H), 1.26-1.37 (m, 4H), 1.49-1.70 (m, 4H), 1.91-1.98 (m, 
lH), 4.23-4.38 (m, 2H), S.03-S.13 (m, 3H), S.67-S.73 (m, lS 
lH), 7.21-7.32 (m, 6H); HRMS (calculated for M+l, 
C12H31N2 0 6 , 407.2182) m/e 407.2178; Sb, TLC (solvent A) 
Rf=0.31; 1H NMR (CDC13 ) o=0.70-0.76 (m, lH), 0.79-0.90 
(m, 6H), 1.22-1.61 (m, SH), 2.93-3.07 (m, lH), 3.19-3.28 (m, 
lH), 4.14-4.33 (m, 3H), S.08 (dd, 14.2S, 12.60, 12.30 Hz, 20 
2H), S.23-S.43 (m, 2H), 6.77-6.84 (m, lH), 7.12-7.29 (m, 
SH), 7.33 (s, SH); HRMS (calculated for M+l, C26H33N20 6 , 
469.2339) m/e 469.2337. 
TABLE2 
Dakin-WestAcylation and Hydrolysis Reaction Conditions. 
Di pep- Ethyl Re- Hydro-
Entry tide Pyri- Oxalyl flux lysis 
No. Acid DMAPa dine a Chloridea Time Time 
3a 0.03 eq 3 eq 2.1 eq 4hr 1 hr 
2 3a O.OS eq 3 eq 2.1 eq 4hr 1 hr 
3a O.OS eq 4 eq 2.1 eq 6 hr 1 hr 
4 3a 0.10 eq 4 eq 2.1 eq 6 hr 1 hr 
3b 0.00 eq 4 eq 2.1 eq 4hr 1 hr 
3b 0.01 eq 3 eq 2.1 eq 3 hr 1 hr 
7 3b 0.03 eq 3 eq 2.0 eq 3 hr 1 hr 
3b O.OS eq 4 eq 2.1 eq 4hr 1 hr 
9 3b 0.10 eq 4 eq 2.1 eq 2hr 1 hr 
10 3b 0.10 eq 4 eq 2.1 eq 2hr 4hr 
11 3b 0.10 eq 4 eq 2.1 eq 4hr 2hr 
12 3b 0.10 eq 4 eq 2.1 eq 4hr 1 hr 
13 3b 0.10 eq 4 eq 2.1 eq S hr 1 hr 
14 3b 0.10 eq 4 eq 2.1 eq 6 hr 1 hr 
lS 3b 0.10 eq 3 eq 2.1 eq S hr 1 hr 
16 3b 0.10 eq Seq 2.1 eq S hr 1 hr 
17 3b 0.20 eq 4 eq 2.1 eq S hr 1 hr 
18 3b 0.20 eq 4 eq 3.1 eq S hr 2 hrc 
"Expressed in molar equivalents relative to the dipeptide acid used. 





















cTwo molar equivalents oftriethyl amine were required to complete the hydrolysis reaction. 
The dipeptide ketoester Sa is Z-Leu-Abu-CO-OEt, and Sb is Z-Leu-Phe-CO-OEt (all com-








1.93-1.97 (m, lH), 4.3S (m, lH), S.04-S.13 (m, 3H), S.82 (m, 
lH), 7.32 (s, SH); HRMS (calculated for M+l, C19H27N20 6 , 
379.1869) m/e 379.1870. 
Example 4 
Synthesis ofN-Cbz-Leu-Phe-COOH (6b) 
The above hydrolysis conditions were followed using S.2S 
g (0.011 mole)ofSbto give4.33 g(0.0098mole, 89%) of pale 
yellow hygroscopic flakes: 1H NMR (CDC13 ) o=0.77-0.86 
(m, SH), l.09-l.S6 (m, 3H), 2.49-2.Sl (m, lH), 2.7S-2.91 (m, 
lH), 3.08-3.18 (m, lH), 4.01-4.08 (m, lH), 4.89-S.06 (m, 
3H), 7.18-7.40 (m, 12H), 8.49 (t, 7.20, 7.20 Hz, lH); HRMS 
(calculated for M+l, C24H29N2 0 6 , 441.2026) m/e 44l.202S. 
Example S 
Synthesis of 9-(3-aminopropyl)adenine 







Synthesis ofN-Cbz-Leu-Abu-COOH (6a) 
A mixture of adenine, l-bromo-3-chloropropane, and 
potassium carbonate in DMF was stirred at room temperature 
ss under argon for 4 days, filtered and evaporated to dryness. 
The crude product was washed with water and dried. Recrys-
tallization from ethanol gave 9-(3-chloropropyl)adenine. 
To a mixture of SAS g (0.013 mole) of Sa in 10 mL of 
methanol, 13 mL of 1 M NaOH solution was added in por-
tions while stirring in an ice bath. The resulting mixture was 
stirred at room temperature for an hour and extracted with 
anhydrous ether ( 4x30 mL). The aqueous layer was acidified 
A mixture of9-(3-chloropropyl)adenine and sodium azide 
in DMF was stirred at 80° C. for 24 hours, cooled to room 
60 temperature and filtered. The solid was washed with CH2 Cl2 . 
to pH 4 with 2 M HCl in an ice bath and extracted with Et20 
(2xSO mL). The combined ether extract was washed with 
saturated NaCl, dried over MgS04 overnight, and filtered. 
Ether was removed from the filtrate by evaporation and the 
product was dried under reduced pressure to give 3.64 g 6S 
(0.0096 mole, 96%) of pale yellow hygroscopic flakes: 1H 
NMR (CDC13 ) o=0.91 (d, 6.3 Hz, 9H), 1.47-1.7S (m, SH), 
The solvent was removed from the combined filtrates and the 
residue was taken up in water with sonication. The aqueous 
layer was extracted with CH2Cl2 . After removing the solvent, 
the crude product was recrystallized from ethanol to give 
9-(3-azidopropyl)adenine as a white crystalline solid. 
A mixture of 9-(3-azidopropyl)adenine and S% palladium 
on carbon in methanol was reacted with hydrogen gas at room 
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temperature for 22 hours. The catalyst was removed by filtra-
tion, the solvent was removed to give 9-(3-aminopropyl)ad-
enine as a white solid. The reference for the synthetic proce-
dure is Zhang et al., "Syntheses and coordination chemistry 
of aminomethylphosphine derivatives of adenine," Euro. J. 
Inorg. Chem. 13:2426-37, 2003, which is incorporated by 
reference herein in its entirety. 
Example 6 
Synthesis of 1-(3-aminopropyl)cytosine 
Scheme 11. Procedure for the synthesis of 1-(3-aminopropyl)cytosine. 
A mixture ofN-acetylcytosine, l-bromo-3-chloropropane, 
and potassium carbonate in DMF was stirred at room tem-
perature under argon for 4 days, filtered and evaporated to 
dryness. The crude product was purified by colunm chroma-
tography and gave l-(3-chloropropyl)-N4-acetylcytosine. 
A mixture of l-(3-chloropropyl)-N4-acetylcytosine and 
sodium azide in acetonitrile was refluxed for 24 hours, cooled 
to room temperature, and filtered. The crude product was 
purified by silica gel column chromatography and gave l-(3-
azidopropyl)-N4-acetylcytosine as a white solid. 
A mixture of l-(3-azidopropyl)-N4-acetylcytosine was 
reacted with 7N ammonia solution in methanol at room tem-
perature for 2 days to give 1-(3-azidopropyl)cytosine as a 
white solid. 
A mixture of 1-(3-azidopropyl)cytosine and 5% palladium 
on carbon in methanol was reacted with hydrogen gas at room 
temperature for 8 h. The catalyst was removed by filtration, 
the solvent was removed to give 1-(3-aminopropyl)cytosine 
as a white solid. The references for this synthesis are Zhang et 
al. "Syntheses and coordination chemistry of aminometh-
ylphosphine derivatives of adenine," Euro. J. Inorg. Chem. 
13:2426-37, 2003; Surmners et al., "Synthesis of Fluorescent 
34 
Labeled Derivatives of Aminopropylpyrimidines," J. Org. 
Chem. 40(11): 1559-61, 1975; and Lafitte et al., "Quadruply 
hydrogen bonded cytosine modules for supramolecular appli-
cations," J. Am. Chem. Soc. 128(20):6544-5, 2006, each of 


















A solution of N-(3-bromopropyl)phthalimide in xylene 
was added dropwise to a solution of 1-methylpiperzazine in 
50 xylene at 70° C. After addition was complete, the mixture was 
heated under reflux for 20 hours. A precipitate was removed 
by filtration and the filtrate was concentrated. The crude prod-
uct was purified by silica gel colunm chromatography to give 
the product N-(3-( 4-methy lpiperazin-1-y l)propy l)phthalim-
55 ide as an oil. 
A solution of N-(3-(4-methylpiperazin-1-yl)propyl)ph-
thalimide and hydrazine monohydrate in ethanol and metha-
nol was refluxed for 4 hours. After cooling to room tempera-
ture, concentrated HCl was added and the mixture heated 
60 under reflux for another hour. After removing the solvent, 
water was added, the mixture stirred, and insoluble material 
removed by filtration. Solid K2C03 and CH2 Cl2 were added 
to the aqueous layer, the mixture stirred, and was then filtered. 
The organic layer was washed with water. The combined 
65 aqueous layers were washed with Et20. Water was removed 
from the organic layers, they were then dried and evaporated 
to give 1-(3-aminopropyl)-4-methylpiperazine as an oil. A 
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reference for this synthesis is Hou et al., "Efficient syntheses 
of oncinotine and neooncinotine," J. Org. Chem. 
69(18):6094-9, 2004, which is incorporated by reference 
herein. 
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CH2 ), 3.3S (S, 2H, NH2 ), 4.20 (m, 2H, CH2 ), 7.20 (s, 2H, 
NH2 ), 8.10 (s, 2H, CH). MS (ED+): 193.0. 
Nucleotide bases with substituents can be synthesized by 5 
similar procedures starting from the appropriate nucleotide 
base. For example, the 2-methoxy derivative of adenine can 
The ketoamide product Z-Leu-Abu-CONH-(CH2 kad-
enin-9-yl was obtained from 9-(3-aminopropyl)adenine and 
the ketoacid Z-Leu-Abu-COOH (30) using the EDC/HOBt 
coupling method, purified by column chromatography on 
silica gel with SS:lS CH2Cl2 :MeOH as the eluant, then 
recrystallization from CH3 COOEt/hexane to give a white 
solid (27% yield). 1H NMR (CDC13 ): o=0.91 (m, 9H, CH3 of 
Val and Abu), 1.60-1.80 (m, SH, CH2 and CH of Leu and 
Abu), 2.00 (m, 2H, CH2 ), 3.20 (2H, CH2 ), 4.24 (m, 3H, CH2 
and a-H), S.11 (s, 2H, Z), S.20 (m, lH, a-H), 6.20 (s, lH, 
NH), 6.80 (b, lH, NH), 7.20-7.40 (m, 6H, Ph and NH), 7.SS 
(d, lH, CH of adenine), 8.36 (d, 111, CH of adenine). HRMS 
(FAB) for C27H37N80 5 : m/z SS3.28S6, calcd. SS3.2881. 
be synthesized via the procedure shown in FIG. 14. Introduc-
tion of a 2-methoxy group on the adenine ring would involve 
reaction of 2-chloroadenine with sodium methoxide to pro- 10 
duce 2-methoxyadenine. Then the same reaction scheme as 
shown in Scheme 10 can be used to attach the spacer onto the 
9-position of the 2-methoxyadenine. 
Scheme 13. Procedure for the 
synthesis of9-(3-aminopropyl)-2-methoxyadenine. 
N:XNH2 N) 
A I ~ NaOMe MeOH Cl ::::::,._N ~ 
~JXN>~ 
MeO N ~ 
i) BrCH,cH,cH,CI, K,co,, DMF ii) NaN3, DMF iii) H,, Pd/C, MeOH 
Example 8 
Synthesis of 3-(Benzyloxycarbonyl-L-leucylamino )-
N -(3-( 6-amino-9H-purin-9-y l)propy 1)-2-oxopentana-
mide (Z-Leu-Abu-CONH-(CH2 ) 3 -adenin-9-yl) 
A mixture of adenine ( 4.0S g, 30 mM), l-bromo-3-chloro-
propane (21.3 g, 13.4 mM), and potassium carbonate (10.4 g, 
7S mM) in DMF (200 mL) was stirred at room temperature 
under argon for 4 days, filtrated, and evaporated to dryness. 
The crude product was washed with water and dried. Recrys-
tallization from ethanol gave 9-(3-chloropropyl)adenine in 
S9%yield. 
A mixture of9-(3-chloropropyl)adenine (1.9 g, 9 mM) and 
sodium azide (1.7S g, 27 mM) in DMF was stirred at 80° C. 
for 24 hours, cooled to room temperature, and filtered. The 
solid was washed with CH2 Cl2 . The solvent was removed 
from the combined filtrates and the residue was taken up in 
water with sonication. The aqueous layer was extracted with 
CH2 Cl2 (3x60 mL). After removing solvent, the crude prod-
uct was recrystallized from ethanol to give 9-(3-azidopropyl) 








A solution of N-(3-bromopropyl)phthalimide (8.04 g, 30 
mM) in xylene (60 mL) was added dropwise to a solution of 
25 1-methylpiperazine (6.61 g, 66 mM) in xylene (90 mL) at 70° 
C. After the addition was complete, the mixture was heated 
under reflux for 20 hours. A precipitate was removed by 
filtration and the filtrate was concentrated. The crude product 
was purified by silica gel chromatography with 9:1 CH2 Cl2 : 
30 MeOH to give the product N-(3-(4-methylpiperazin-1-yl) 
propyl)phthalimide as an oil in 72% yield. 
A solution of N-(3-(4-methylpiperazin-1-yl)propyl)ph-
thalimide ( 6.2 g, 21.6 mM) and hydrazine monohydrate (1.13 
g, 26 mM) in ethanol (60 mL) and methanol (60 mL) was 
35 refluxed for 4 hours. After cooling to room temperature, con-
centrated HCl (2.4 mL) was added and the mixture heated 
under reflux for another hour. After removing the solvent, 
water (100 mL) was added, the mixture stirred and insoluble 
material removed by filtration. Solid K2 C03 (1.2 eq) and 
40 CH2Cl2 (100 mL) was added to the aqueous layer; the mixture 
stirred, and was then filtered. The organic layer was washed 
with water (3x20 mL). The combined aqueous layers were 
washed with Et2 0. Water was removed from the organic 
layers, which were then dried and evaporated to give 1-(3-
45 aminopropyl)-4-methylpiperazine as an oil in 39% yield. 1H 
NMR (CDC13 ): o=l .SS (m, 2H, CH2 ), 2.20 (s, 3H, CH3 ), 2.34 
(t, 2H, CH2 ), 2.67 (t, 2H, CH2 ). MS (ES+): 1S7.9. 
The ketoamide Z-Leu-Abu-CONH-(CH2 k(4-meth-
ylpiperazin-1-yl) was synthesized from 1-(3-aminopropyl)-
50 4-methylpiperazine and Z-Leu-Abu-COOH (30) using the 
EDC/HOBt coupling method, purified twice by colunm chro-
matography on silica gel using 80:20 CH2 Cl2 :MeOH and 
SS:lS CH2Cl2 :MeOH as the eluant to give a yellow semi-
solidin 16%yield. 1HNMR(CDC13 ): o=0.91(m,9H, CH3 of 
55 Val and Abu), 1.60-1.80 (m, SH, CH2 and CH), 2.00 (m, 2H, 
CH2 ), 2.44 (s, 3H, CH3 ofpiperazine), 2.S0-2.6S (m, SH, CH2 
of piperazine), 3.30 (m, 2H, CH2 ), 4.20 (m, 3H, CH2 and 
a-H), S.10 (s, 2H, Z), S.lS (m, lH, a-H), 6.70 (b, lH, NH), 
7.20-7.30 (m, 6H, Ph and NH), 8.60 (b, lH, NH). HRMS 
60 (FAB) for C27H44N5 0 5 : m/z SlS.3301. 
A mixture of 9-(3-azidopropyl)adenine (O.S g, 2.3 mM) 
and S% palladium on carbon (O.S g) in methanol was reacted 
with hydrogen gas at room temperature for 22 hours. The 
catalyst was removed by filtration, the solvent removed to 65 
give 9-(3-aminopropyl)adenine as a white solid in 76% yield. 
Example 10 
The dipeptide ketoamide was obtained from the blocked 
derivative Z-Leu-NHCH(C2H5 )C(-S(CH2 ) 2 S-)C0-0Et 1H NMR (DMSO-d6 ): o=l.80 (m, 2H, CH2 ), 2.4S (m, 2H, 
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and (CH3)2N(CH2)3NH2 in THF at room temperature for 12 
hours. Purification by colunm chromatography twice on 
silica gel with 80:20 CH2Cl2:MeOH and 8S:1S CH2Cl2: 
38 
erythrocytes according to the method ofKitahara (Kitahara et 
al., J. Biochem. 9S: 17S9-66) omitting the Blue-Sepharose 
step. Calpain II from rabbit muscle and cathepsin B were 
MeOH as the eluant provided a yellow semi-solid in 11 % 
yield. 1 H NMR (CDCl3): o=0.91 (m, 9H, CH3 of Val and 5 
Abu), 1.S0-1.70 (m, SH, CH2 and CH), 2.00 (m, 2H, CH2), 
2.70 (s, 6H, CH3), 3.40 (m, 2H, CH2), 4.20 (m, 2H, CH2), 4.30 
(b, lH, a-H), S.10 (s, 2H, Z), S.40 (m, lH, a-H), 6.40 (b, lH, 
NH), 7.20-7.30 (m, 6H, Ph and NH), 7.80 (b, lH, NH). 
HRMS (FAB) for C24H39N40 5 : m/z 463.2973. 10 
purchased from Sigma. Papain was purchased from Calbio-
chem. 
Assay of Inhibitory Potency. 
Peptide a-ketoamides were assayed as reversible enzyme 
inhibitors. Various concentrations of inhibitors in Me2SO 
were added to the assay mixture, which contained buffer and 
substrate. The reaction was started by the addition of the 
enzyme and the hydrolysis rates were followed spectropho-
Example 11 
The dipeptide ketoamide was obtained from Z-Leu-Phe-
COOH and (CH3)2N(CH2)3NH2 using the EDC/HOBt cou-
pling method. Purification by colunm chromatography twice 
on silica gel with 80:20 CH2Cl2:MeOH as the eluant, then by 
TLC, provided a yellow semi-solid, in 10% yield. 1H NMR 
(CDCl3): o=0.84 (m, 6H, CH3 ofVal), 1.S0-1.80 (m, SH, CH2 
and CH), 2.12 and2.19 (d, 6H, CH3), 3.00 (m, 2H, CH2), 3.20 
(m, 2H, CH2), 4.lS (m, 2H, CH2), 4.SO (b, lH, a-H), S.10 (m, 
3H, Zand a-H), 6.82 (b, lH, NH), 7 .OS-7 .30 (m, 6H, Ph and 
NH), 7.40 (b, lH, NH). HRMS (FAB) forC29H41N40 5 : m/z 
S2S.3077. 
Example 12 
The dipeptide ketoamide was obtained from Z-Leu-Phe-
COOH and (CH3)2N(CH2)2NH2 using the EDC/HOBt cou-
pling method. Purification twice by colunm chromatography 
on silica gel with 80:20 CH2Cl2:MeOH as the eluant, and then 
by TLC, gave a yellow semi-solid in 7% yield. 1H NMR 
(CDCl3): o=0.8S (m, 6H, CH3 ofVal), 1.S0-1.70 (m, 3H, CH2 
and CH), 2.46 (s, 6H, CH3), 3.00 (m, 2H, CH2), 4.20 (m, 2H, 
CH2), 4.31 (m, 2H, CH2), 4.90 (b, lH, a-H), S.00 (m, 3H, Z 
and a-H), 6.20 (b, lH, NH), 7.00-7.30 (m, 7H, Ph and NH). 




The dipeptide ketoamide was obtained from Z-Leu-Phe-
COOH and l-methyl-4-(3-aminopropyl)piperazine using the 
EDC/HOBt coupling method. Purification twice by column 
chromatography on silica gel with 8S:1S CH2Cl2:MeOH as 
the eluant gave a yellow semi-solid in 10% yield. 1H NMR 
(CDCl3): o=0.81 (m, 6H, CH3 ofVal), 1.40-1.60 (m, SH, CH2 
and CH), 2.28 (s, 6H, CH3), 3.00 (m, 2H, CH2), 3.20 (m, 2H, 
CH2), 4.0S (m, 2H, CH2), 4.SO (b, lH, a-H), S.02 (m, 3H, Z 
and a-H), 6.70 (b, lH, NH), 7.0S-7.30 (m, 7H, Ph and NH). 
Example 14 
Fluorimetric analysis of µI-II and m-calpain inhibi-
tion by Z-Leu-Abu-CONH-(CH2kadenin-9-yl, 
and Z-Leu-Abu-CONH-(CH2k( 4-methylpiper-
azin-1-yl) 
tometrically or fluorimetrically. 
Calpain I from human erythrocytes and calpain II from 
rabbit were assayed using Suc-Leu-Tyr-AMC (Sasaki et al., J. 
15 Biol. Chem. 2S9: 12489-94, 1984, which is incorporated by 
reference herein), and the AMC (7-amino-4-methylcou-
marin) release was followed fluorimetrically (excitation at 
380 nm, and emission at 460 nm). Calpains were assayed in 
2S mM Tris pH=8.0, 10 mM CaCl2. Fluorescence was fol-
20 lowed using a Gilson FL-IA fluorometer or a Perkin-Elmer 
203 Fluorescence spectrometer. Cathepsin B was assayed in 
20 mM sodium acetate pH=S.2, O.S mM dithiothreitol using 
Bz-Phe-Val-Arg-p-nitroanilide as substrate. Alternately, 
cathepsin B was assayed with Z-Arg-Arg-AFC (Barrett and 
25 Kirschke, Methods Enzymol. 80:S3S-S6l, 1981, which is 
incorporated by reference herein), and the AFC (7-amino-4-
trifluoromethylcoumarin) release was followed fluorimetri-
cally (excitation at 400 nm and emission at SOS nm). Papain 
was assayed in 100 mM KP04, 1 mM EDTA, 2.S mM cys-
30 teine pH=6.0 using Bz-Arg-AMC or Bz-Arg-NA (Kanaoka et 
al., Chem. Pharm. Bull. 2S:3126-8, 1977, which is incorpo-
rated by reference herein) as a substrate. The AMC (7-amino-
4-methylcoumarin) release was followed fluorimetrically 
(excitation at 380 nm, and emission at 460 nm). Enzymatic 
35 hydrolysis rates were measured at various substrate and 
inhibitor concentrations, and KI values were determined by 
either Lineweaver-Burk plots or Dixon plots. 
A SO mM Tris.RC!, 2 mM EDTA, S mM cysteine, pH 7.S 
was used as a buffer for papain. A 88 mM KH2P04, 12 mM 
40 Na2HP04, 1.33 mM EDTA, 2.7 mM cysteine, pH 6.0 solution 
was used as a buffer for cathepsin B. A 20 mM Hepes, 10 mM 
CaCl2, 10 mM mercaptoethanol, pH 7.2 buffer was utilized 
for calpain I and calpain II. 
Enzymatic activity was monitored in real-time using a l .S 
45 mL quartz cuvette and a Perkin-Elmer LSSO-B Lumines-
cence Spectrophotometer. Duplicate assays were performed 
with 1.3 µM (EDANS)-EPLFAERK(SEQ ID NO:l)-(DAB-
CYL) and 12S nM µI-II or m-calpain in a buffer solution 
containing SO mM HEPES-HCI (pH 7.7) and 10 mM DTT. 
50 The reaction was initiated 420 seconds after mixing by the 
addition of 4 mM CaCl2 and monitored at excitation and 
emission wavelengths of 33S nm and SOO nm, respectively. 
After a waiting period of 100 seconds, the inhibitor solution 
(either Z-Leu-Abu-CONH-(CH2kadenin-9-yl, or Z-Leu-
55 Abu-CONH-(CH2k( 4-methylpiperazin-1-yl) dissolved in 
DMSO) was added at a concentration of 1 µM (for the 
m-calpain assays) or SO µM (for the µI-II assays). Control 
assays were performed by adding an equivalent volume of 
60 
D MSO after the 100-second delay. 
Evaluating the inhibitory potency of Z-Leu-Abu-CONH-
(CH2kadenin-9-yl and Z-Leu-Abu-CONH-(CH2k(4-
methylpiperazin-1-yl) on and m-calpain. 
HEPES, heparin, andA23187 were obtained from Calbio- 65 
chem. Suc-Leu-Tyr-AMC and chromogenic substrates were 
obtained from Sigma. Calpain I was purified from human 
Upon calcium activation, the rate of cleavage of the FRET 
substrate by m-calpain (FIG. lA) was approximately four 
times higher than that catalyzed by (FIG. lB). In the absence 
of either inhibitor, the autolytic inactivation of m-calpain 
caused the fluorescence intensity to plateau after just a few 
US 8,518,885 B2 
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minutes of reaction. However, this autolytic inactivation was 
not observed with Upon addition of either inhibitor, the 
increase in fluorescence was immediately attenuated, albeit 
more noticeably with m-calpain. For both m-calpain and µI-
II, Z-Leu-Abu-CONH-(CH2kadenin-9-yl, caused a more 
distinct attenuation of fluorescence when compared to Z-Leu-
Abu-CONH-(CH2)3-( 4-methylpiperazin-1-yl), indicating 
that the former is a more potent calpain inhibitor. See FIG. 1. 
It will be apparent to those skilled in the art that various 
modifications and variations can be made in the present 10 
invention without departing from the scope or spirit of the 
invention. Other embodiments of the invention will be appar-
ent to those skilled in the art from consideration of the speci-
fication and practice of the invention disclosed herein. It is 
intended that the specification and examples be considered as 15 
exemplary only, with a true scope and spirit of the invention 
being indicated by the following claims. 
<160> NUMBER OF SEQ ID NOS, 1 
<210> SEQ ID NO 1 
<211> LENGTH, 8 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic Construct 
<400> SEQUENCE, 1 
Glu Pro Leu Phe Ala Glu Arg Lys 
1 5 
What is claimed is: 
1. A compound comprising the formula M-AA2-AA1 -
CO-NH-(CH2)n-R3 or a pharmaceutically acceptable 
salt thereof, wherein 
M is selected from the group consisting of NH2---CO-, 










FG is selected from the group cons1stmg of -CO-, 
---0-CO-, -NH---CO-, -S02-, -NH- 55 
S02-, and -NH-CS; 
Y is selected from the group consisting ofC1_8 alkyl, C3_15 
cycloalkyl, cl-4 alkylmonosubstituted with phenyl, cl-4 
alkyl disubstituted with phenyl, C1 _4 alkyl monosubsti-
tuted with Ar, C1_4 alkyl monosubstituted with 1-naph- 60 
thy!, C1 _4 alkyl monosubstituted with 2-naphthyl, and 
Ar; 
wherein Ar is selected from the group consisting of phenyl, 
phenyl monosubstituted with J, phenyl disubstituted 
with J, 1-naphthyl, 1-naphthyl monosubstituted with J, 65 
2-naphthyl, 2-naphthyl monosubstituted with J, 2-py-
ridyl, 3-pyridyl, and 4-pyridyl; 
40 
J is selected from the group consisting ofhalogen, OH, CN, 
N02, NH2, COOH, C02Me, C02Et, CF3, C1 _6 alkyl, 
cl-4 alkoxy, and cl-4 perfluoroalkyl; 
AA 2 is a residue of an amino acid with the L configuration, 
D configuration, or DL configuration at the a-carbon 
selected from the group consisting of alanine, valine, 
leucine, isoleucine, praline, histidine, methionine, 
methionine sulfoxide, phenylalanine, serine, threonine, 
pheny !glycine, norleucine, norvaline, alpha-amino bu-
tyric acid, 0-methylserine, 0-ethylserine, S-methylcys-
teine, S-ethylcysteine, S-benzylcysteine, NH2---CH 




trifluoroleucine, a-aminohexanoic acid, thiaproline, 
and hexafluoroleucine; 
AA 1 is a residue of glycine or a residue of an amino acid 
with the L configuration, D configuration, or DL con-
figuration at the a-carbon selected from the group con-
sisting of alanine, valine, leucine, isoleucine, praline, 
histidine, methionine, methionine sulfoxide, phenylala-
nine, arginine, lysine, tryptophan, serine, threonine, cys-
teine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, 0-methylserine, 0-eth-
ylserine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2---CH(CH2CHEt2)-COOH, alpha-ami-






anoic acid, phenylalanine monosubstituted on the phe-
nyl group with K, and homophenylalanine monosubsti-
tuted on the phenyl group with K; 
K is selected from the group consisting of halogen, C1 _6 
alkyl, and cl-4 alkoxy; 
n=l-5; 













































R4 is selected from the group consisting of C1 _6 alkyl, 
phenyl, and benzyl; 
5 10 R is selected from the group consisting of C1 _6 alkyl, 
phenyl, and benzyl; and 
R6 is selected from the group consisting of C1 _6 alkyl, 
phenyl, and benzyl. 
2. The compound of claim 1, or a pharmaceutically accept- 15 




i1o R' ~1o 
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3. The compound of claim 2, or a pharmaceutically accept-
able salt thereof, wherein FG is selected from the group 








AA 2 is a residue of an amino acid with the L configuration, 55 
D configuration, or DL configuration at the a-carbon 
selected from the group consisting of alanine, valine, 
leucine, isoleucine, praline, histidine, methionine, 
methionine sulfoxide, phenylalanine, serine, threonine, 
phenylglycine, norleucine, norvaline, alpha-aminobu- 60 
tyric acid, 0-methylserine, 0-ethylserine, S-methylcys-
teine, S-ethylcysteine, S-benzylcysteine, and alpha-
aminoheptanoic acid; and 
AA 1 is a residue of glycine or a residue of an amino acid 
with the L configuration, D configuration, or DL con- 65 
figuration at the a-carbon selected from the group con-
sisting of alanine, valine, leucine, isoleucine, praline, 
44 
histidine, methionine, methionine sulfoxide, phenylala-
nine, arginine, lysine, tryptophan, serine, threonine, cys-
teine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, 0-methylserine, 0-eth-
ylserine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, alpha-aminoheptanoic acid, NH2-CH(CH2 -
l-naphthyl)-COOH, NH2-CH(CH2 -2-naphthyl)-
COOH, homophenylalanine, hexafluoroleucine, and 
a-aminohexanoic acid. 
4. The compound of claim 3, or a pharmaceutically accept-
able salt thereof, wherein R4 is selected from the group con-
sisting of C1 _6 alkyl; R5 is selected from the group consisting 
ofC1 _6 alkyl; and R6 is selected from the group consisting of 
cl-6alkyl. 
5. The compound of claim 1, or a pharmaceutically accept-
able salt thereof, wherein R3 is 
6. The compound of claim 5, or a pharmaceutically accept-
able salt thereof, wherein FG is selected from the group 
consisting of -CO-, -0---CO-, and -NH-CO-; 
AA 2 is a residue of an amino acid with the L configuration, 
D configuration, or DL configuration at the a-carbon 
selected from the group consisting of alanine, valine, 
leucine, isoleucine, praline, histidine, methionine, 
methionine sulfoxide, phenylalanine, serine, threonine, 
pheny !glycine, norleucine, norvaline, alpha-amino bu-
tyric acid, 0-methylserine, 0-ethylserine, S-methylcys-
teine, S-ethylcysteine, S-benzylcysteine, and alpha-
aminoheptanoic acid; and 
AA 1 is a residue of glycine or a residue of an amino acid 
with the L configuration, D configuration, or DL con-
figuration at the a-carbon selected from the group con-
sisting of alanine, valine, leucine, isoleucine, praline, 
histidine, methionine, methionine sulfoxide, phenylala-
nine, arginine, lysine, tryptophan, glycine, serine, threo-
nine, cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, phenylglycine, norleucine, norval-
ine, alpha-aminobutyric acid, 0-methylserine, 0-eth-
ylserine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, alpha-aminoheptanoic acid, NH2-CH(CH2 -
l-naphthyl )-COO H, NH2-CH( CH2 -2-naphthy 1)-
COO H, homophenylalanine, hexafluoroleucine, and 
a-aminohexanoic acid. 
7. The compound of claim 6, or a pharmaceutically accept-
able salt thereof, wherein FG is selected from the group 
consisting of ---0---CO- and -NH-CO-. 
8. The compound of claim 1, or a pharmaceutically accept-
able salt thereof, wherein R3 is selected from the group con-
sisting of 
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9. The compound of claim8, or a pharmaceutically accept-
able salt thereof, wherein FG is selected from the group 35 
consisting of -CO-, -0---CO-, and -NH-CO-; 
AA 2 is a residue of an amino acid with the L configuration, 
D configuration, or DL configuration at the a-carbon 
selected from the group consisting of alanine, valine, 40 
leucine, isoleucine, praline, histidine, methionine, 
methionine sulfoxide, phenylalanine, serine, threonine, 
phenylglycine, norleucine, norvaline, alpha-aminobu-
tyric acid, 0-methylserine, 0-ethylserine, S-methylcys-
teine, S-ethylcysteine, S-benzylcysteine, and alpha- 45 
aminoheptanoic acid; and 
AA 1 is a residue of glycine or a residue of an amino acid 
with the L configuration, D configuration, or DL con-
figuration at the a-carbon selected from the group con-
sisting of alanine, valine, leucine, isoleucine, praline, 50 
histidine, methionine, methionine sulfoxide, phenylala-
nine, arginine, lysine, tryptophan, serine, threonine, cys-
teine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, 0-methylserine, 0-eth- 55 
ylserine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, alpha-aminoheptanoic acid, NH2-CH(CH2 -
l-naphthyl)-COOH, NH2---CH(CH2 -2-naphthyl)-
COOH, homophenylalanine, hexafluoroleucine, and 
a-aminohexanoic acid. 60 
10. The compound of claim 9, or a pharmaceutically 
acceptable salt thereof, wherein R4 is C1 _6 alkyl; Rs is C1_6 
alkyl; and R 6 is C1 _6 alkyl. 
11. The compound of claim 1, or a pharmaceutically 65 
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12. The compound of claim 11, or a pharmaceutically 
acceptable salt thereof, wherein FG is selected from the group 
consisting of -CO-, -0---CO-, and -NH-CO-; 
AA 2 is a residue of an amino acid with the L configuration, 
D configuration, or DL configuration at the a-carbon 
selected from the group consisting of alanine, valine, 
leucine, isoleucine, praline, histidine, methionine, 
methionine sulfoxide, phenylalanine, serine, threonine, 
pheny !glycine, norleucine, norvaline, alpha-amino bu-
tyric acid, 0-methylserine, 0-ethylserine, S-methylcys-
teine, S-ethylcysteine, S-benzylcysteine, and alpha-
aminoheptanoic acid; and 
AA 1 is a residue of glycine or a residue of an amino acid 
with the L configuration, D configuration, or DL con-
figuration at the a-carbon selected from the group con-
sisting of alanine, valine, leucine, isoleucine, praline, 
histidine, methionine, methionine sulfoxide, phenylala-
nine, arginine, lysine, tryptophan, serine, threonine, cys-
teine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, 0-methylserine, 0-eth-
ylserine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, alpha-aminoheptanoic acid, NH2-CH(CH2 -
l-naphthyl )-COO H, NH2-CH( CH2 -2-naphthy 1)-
COO H, homophenylalanine, hexafluoroleucine, and 
a-aminohexanoic acid. 
13. The compound of claim 12, or a pharmaceutically 
acceptable salt thereof, wherein R4 is C1_6 alkyl; Rs is C1 _6 
alkyl; and R6 is C1 _6 alkyl. 
14. A compound, or a pharmaceutically acceptable salt 
thereof, selected from the group consisting of 
Z-Leu-Abu-CONH-(CH2 ) 3 -adenin-9-yl, 
Z-Leu-Phe-CONH-(CH2 ) 3 -adenin-9-yl, 
Z-Leu-Hph-CONH-(CH2 ) 3 -adenin-9-yl, 
Z-Val-Abu-CONH-(CH2 ) 3 -adenin-9-yl, 
Z-Val-Phe-CONH-(CH2 ) 3 -adenin-9-yl, 
Z-Val-Hph-CONH-(CH2kadenin-9-yl, 
Z-Leu-Abu-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
Z-Leu-Phe-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
Z-Leu-Hph-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
Z-Val-Abu-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
Z-Val-Phe-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
Z-Val-Hph-CONH-( CH2 ) 3 -2-methyladenin-9-y I, 
Z-Leu-Abu-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
Z-Leu-Phe-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
Z-Leu-Hph-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
Z-Val-Abu-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
Z-Val-Phe-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
Z-Val-Hph-CONH-( CH2 ) 3 -2-methoxyadenin-9-y I, 
Z-Leu-Abu-CONH-(CH2 ) 3 -cytosin-3-yl, 
Z-Leu-Phe-CONH-(CH2 ) 3 -cytosin-3-yl, 
Z-Leu-Hph-CONH-(CH2 ) 3 -cytosin-3-yl, 
Z-Val-Abu-CONH-(CH2 ) 3 -cytosin-3-yl, 
Z-Val-Phe-CONH-(CH2 ) 3 -cytosin-3-yl, 
Z-Val-Hph-CONH-(CH2 ) 3 -cytosin-3-yl, 
Z-Leu-Abu-CONH-(CH2 ) 3 -( 4-methylpiperazin-1-yl), 
Z-Leu-Phe-CONH-(CH2k( 4-methylpiperazin-1-yl), 
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Z-Leu-Hph-CONH-(CH2 ) 3 -( 4-methylpiperazin-1-yl), 
Z-Val-Abu-CONH-(CH2 ) 3 -( 4-methylpiperazin-1-yl), 
Z-Val-Phe-CONH-(CH2k(4-methylpiperazin-1-yl), 
Z-Val-Hph-CONH-(CH2k( 4-methylpiperazin-1-yl), 
Z-Leu-Abu-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Z-Leu-Phe-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Z-Leu-Hph-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Z-Val-Abu-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Z-Val-Phe-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Z-Val-Hph-CONH-(CH2 ) 3-N(CH3 ) 2 , 10 
Z-Leu-Abu-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Z-Leu-Phe-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Z-Leu-Hph-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Z-Val-Abu-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Z-Val-Phe-CONH-(CH2 ) 2-N(CH3 ) 2 , 15 
Z-Val-Hph-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Mu-Leu-Abu-CONH-(CH2 ) 3 -adenin-9-yl, 
Mu-Leu-Phe-CONH-(CH2 ) 3 -adenin-9-yl, 
Mu-Leu-Hph-CONH-(CH2 ) 3 -adenin-9-yl, 
Mu-Val-Abu-CONH-(CH2 ) 3 -adenin-9-yl, 20 
Mu-Val-Phe-CONH-(CH2 ) 3 -adenin-9-yl, 
Mu-Val-Hph-CONH-(CH2 ) 3 -adenin-9-yl, 
Mu-Leu-Abu-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
Mu-Leu-Phe-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
Mu-Leu-Hph-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 25 
Mu-Val-Abu-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
Mu-Val-Phe-CONH-( CH2 ) 3 -2-methyladenin-9-y I, 
Mu-Val-Hph-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
Mu-Leu-Abu-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
Mu-Leu-Phe-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 30 
Mu-Leu-Hph-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
Mu-Val-Abu-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
Mu-Val-Phe-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
Mu-Val-Hph-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
Mu-Leu-Abu-CONH-(CH2 ) 3 -cytosin-3-yl, 35 
Mu-Leu-Phe-CONH-(CH2 ) 3 -cytosin-3-yl, 
Mu-Leu-Hph-CONH-(CH2 ) 3 -cytosin-3-yl, 
Mu-Val-Abu-CONH-(CH2 ) 3 -cytosin-3-yl, 
Mu-Val-Phe-CONH-(CH2 ) 3 -cytosin-3-yl, 
Mu-Val-Hph-CONH-(CH2 ) 3 -cytosin-3-yl, 40 
Mu-Leu-Abu-CONH-(CH2k( 4-methylpiperazin-1-yl), 
Mu-Leu-Phe-CONH-(CH2 ) 3 -(4-methylpiperazin-1-yl), 
Mu-Leu-Hph-CONH-(CH2 ) 3 -(4-methylpiperazin-1-yl), 
Mu-Val-Abu-CONH-(CH2 ) 3 -( 4-methylpiperazin-1-yl), 
Mu-Val-Phe-CONH-(CH2k( 4-methylpiperazin-1-yl), 45 
Mu-Val-Hph-CONH-(CH2 ) 3 -( 4-methylpiperazin-1-yl), 
Mu-Leu-Abu-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Mu-Leu-Phe-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Mu-Leu-Hph-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Mu-Val-Abu-CONH-(CH2 ) 3-N(CH3 ) 2 , 50 
Mu-Val-Phe-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Mu-Val-Hph-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Mu-Leu-Abu-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Mu-Leu-Phe-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Mu-Leu-Hph-CONH-(CH2 ) 2-N(CH3 ) 2 , 55 
Mu-Val-Abu-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Mu-Val-Phe-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Mu-Val-Hph-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Pip-CO-Leu-Abu-CONH-(CH2 ) 3 -adenin-9-yl, 
Pip-CO-Leu-Phe-CONH-( CH2 ) 3 -adenin-9-y I, 60 
Pip-CO-Leu-Hph-CONH-(CH2 ) 3 -adenin-9-yl, 
Pip-CO-Val-Abu-CONH-(CH2 ) 3 -adenin-9-yl, 
Pip-CO-Val-Phe-CONH-(CH2 ) 3 -adenin-9-yl, 
Pip-CO-Val-Hph-CONH-(CH2 ) 3 -adenin-9-yl, 
Pip-CO-Leu-Abu-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 65 
Pip-CO-Leu-Phe-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
Pip-CO-Leu-Hph-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
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Pip-CO-Val-Abu-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
Pip-CO-Val-Phe-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
Pip-CO-Val-Hph-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
Pip-CO-Leu-Abu-CONH-(CH2 ) 3 -2-methoxyadenin-9-
yl, 
Pip-CO-Leu-Phe-CONH-( CH2 ) 3 -2-methoxyadenin-9-
yl, 
Pip-CO-Leu-Hph-CONH-(CH2 ) 3 -2-methoxyadenin-9-
yl, 
Pip-CO-Val-Abu-CONH-(CH2 ) 3 -2-methoxyadenin-9-
yl, 
Pip-CO-Val-Phe-CONH-( CH2 ) 3 -2-methoxyadenin-9-
yl, 
Pip-CO-Val-Hph-CONH-(CH2 ) 3 -2-methoxyadenin-9-
yl, 
Pip-CO-Leu-Abu-CONH-(CH2 ) 3 -cytosin-3-yl, 
Pip-CO-Leu-Phe-CONH-(CH2 ) 3 -cytosin-3-yl, 
Pip-CO-Leu-Hph-CONH-(CH2 ) 3 -cytosin-3-yl, 
Pip-CO-Val-Abu-CONH-(CH2 ) 3 -cytosin-3-yl, 
Pip-CO-Val-Phe-CONH-(CH2 ) 3 -cytosin-3-yl, 
Pip-CO-Val-Hph-CONH-(CH2 ) 3 -cytosin-3-yl, 
Pip-CO-Leu-Abu-CONH-( CH2 ) 3 -( 4-methy lpiperazin-
1-y l), 
Pip-CO-Leu-Phe-CONH-(CH2 ) 3 -( 4-methylpiperazin-1-
yl), 




Pip-CO-Val-Phe-CONH-(CH2 ) 3 -( 4-methylpiperazin-1-
yl), 
Pip-CO-Val-Hph-CONH-(CH2 ) 3 -(4-methylpiperazin-1-
yl), 
Pip-CO-Leu-Abu-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Pip-CO-Leu-Phe-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Pip-CO-Leu-Hph-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Pip-CO-Val-Abu-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Pip-CO-Val-Phe-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Pip-CO-Val-Hph-CONH-(CH2 ) 3-N(CH3 ) 2 , 
Pip-CO-Leu-Abu-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Pip-CO-Leu-Phe-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Pip-CO-Leu-Hph-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Pip-CO-Val-Abu-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Pip-CO-Val-Phe-CONH-(CH2 ) 2-N(CH3 ) 2 , 
Pip-CO-Val-Hph-CONH-(CH2 ) 2-N(CH3 ) 2 , 
PhPr-Leu-Abu-CONH-(CH2 ) 3 -adenin-9-yl, 
PhPr-Leu-Phe-CONH-(CH2 ) 3 -adenin-9-yl, 
PhPr-Leu-Hph-CONH-(CH2 ) 3 -adenin-9-yl, 
PhPr-Val-Abu-CONH-(CH2 ) 3 -adenin-9-yl, 
PhPr-Val-Phe-CONH-(CH2 ) 3 -adenin-9-yl, 
PhPr-Val-Hph-CONH-(CH2 ) 3 -adenin-9-yl, 
PhPr-Leu-Abu-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
PhPr-Leu-Phe-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
PhPr-Leu-Hph-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
PhPr-Val-Abu-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
PhPr-Val-Phe-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
PhPr-Val-Hph-CONH-(CH2 ) 3 -2-methyladenin-9-yl, 
PhPr-Leu-Abu-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
PhPr-Leu-Phe-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
PhPr-Leu-Hph-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
PhPr-Val-Abu-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
PhPr-Val-Phe-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
PhPr-Val-Hph-CONH-(CH2 ) 3 -2-methoxyadenin-9-yl, 
PhPr-Leu-Abu-CONH-(CH2 ) 3 -cytosin-3-yl, 
PhPr-Leu-Phe-CONH-(CH2 ) 3 -cytosin-3-yl, 
PhPr-Leu-Hph-CONH-(CH2 ) 3 -cytosin-3-yl, 
PhPr-Val-Abu-CONH-(CH2 ) 3 -cytosin-3-yl, 
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PhPr-Val-Phe-CONH-(CH2 ) 3 -cytosin-3-yl, 
PhPr-Val-Hph-CONH-(CH2 ) 3 -cytosin-3-yl, 
PhPr-Leu-Abu-CONH-( CH2 ) 3 _4 -methylpiperazin-1-yl ), 
PhPr-Leu-Phe-CONH-(CH2 ) 3 -( 4-methylpiperazin-1-
yl), 
PhPr-Leu-Hph-CONH-(CH2 ) 3 -( 4-methylpiperazin-1-
yl), 
PhPr-Val-Abu-CONH-(CH2 ) 3 -(4-methylpiperazin-1-
yl), 
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17. A method of inhibiting a cysteine protease, comprising: 
contacting the cysteine protease with a compound of claim 1. 
18. The method of claim 17, wherein the contacting occurs 
lllVIVO. 
19. The method of claim 17, wherein the contacting occurs 
in vitro. 
20. The method of claim 17, wherein the cysteine protease 
comprises a calpain. 
PhPr-Val-Phe-CONH-(CH2k( 4-methylpiperazin-1-yl), 10 PhPr-Val-Hph-CONH-(CH2 ) 3 -(4-methylpiperazin-1- 21. The method of claim 17, wherein the cysteine protease comprises a member of the clan CA of cysteine proteases. 
yl), 
PhPr-Leu-Abu-CONH-(CH2 ) 3-N(CH3 ) 2 , 
PhPr-Leu-Phe-CONH-(CH2 ) 3-N(CH3 ) 2 , 
PhPr-Leu-Hph-CONH-(CH2 ) 3-N(CH3 ) 2 , 
PhPr-Val-Abu-CONH-(CH2 ) 3-N(CH3 ) 2 , 
PhPr-Val-Phe-CONH-(CH2 ) 3-N(CH3 ) 2 , 
PhPr-Val-Hph-CONH-(CH2 ) 3-N(CH3 ) 2 , 
PhPr-Leu-Abu-CONH-(CH2 ) 2-N(CH3 ) 2 , 
PhPr-Leu-Phe-CONH-(CH2 ) 2-N(CH3 ) 2 , 
PhPr-Leu-Hph-CONH-(CH2 ) 2-N(CH3 ) 2 , 
PhPr-Val-Abu-CONH-(CH2 ) 2-N(CH3 ) 2 , 
PhPr-Val-Phe-CONH-(CH2 ) 2-N(CH3 ) 2 , and 
PhPr-Val-Hph-CONH-(CH2 ) 2-N(CH3 ) 2 . 
15. The compound of claim 1, wherein said compound 
substantially comprises a single optical isomer. 
16. A pharmaceutical composition comprising an effective 
amount of a compound of claim 1, and a pharmaceutically 
acceptable carrier. 
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22. A method of treating a neurodegenerative disorder, 
comprising: 
administering an effective amount of a compound of claim 
1 to a host having a neurodegenerative disorder or symp-
toms thereof. 
23. The method of claim 22, wherein the neurodegenera-
tive disorder is selected from the group consisting of stroke, 
Alzheimer's disease, Parkinson's disease, multiple sclerosis, 
20 neuropathies, Huntington's disease, dentatorubropallidoluy-
sian atrophy, spinocerebellar atrophy type 3, spinal bulbar 
muscular atrophy, and myotrophic lateral sclerosis. 
24. A method of treatment of nerve degeneration due to 
diabetes or a neurotoxic agent, comprising: administering to 
25 
a patient a therapeutically effective amount of a compound of 
claim 1. 
* * * * * 
